CA2557249A1 - Novel compounds as inhibitors of hepatitis c virus ns3 serine protease - Google Patents

Abstract

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Description

NOVEL COMPOUNDS AS INHIBITORS OF' HEPATITIS C VIRUS

Field of the Invention The present invention relates to novel hepatitis C virus ("HCV") protease inhibitors, pharmaceutical compositions containing one or more such inhibitors, methods of preparing such inhibifiors and methods of using such inhibitors to treat hepatitis C and related disorders. This invention additionally discloses novel compounds as inhibitors of the HCV NS3/NS4a serine protease. This application claims priority from U.S. provisional patent application, Serial Number 60/548,535 filed February 27, 2004.
Backe~round of the invention Hepatitis C virus (HCV) is a (+)-sense single-stranded RNA virus that has been implicated as the major causative agent in non-A, non-B hepatitis (NANBH), particularly in blood-associated NANBH (BB-NANBH) (see, International Patent Application Publication No. WO 89/04669 and European Patent Application Publication No. EP 389 216). NANBH is to be distinguished from other types of viral-induced liver disease, such as hepatitis A virus (HAV), hepatitis B virus (HBV), delta hepatitis virus (HDV), cytomegalovirus (CMV) and Epstein-Barr virus (EBV), as well as from other forms of liver disease such as alcoholism and primary biliar cirrhosis.
Recently, an HCV protease necessary for polypeptide processing and viral replication has been identified, cloned and expressed. (See, e.a., U.S.
Patent No. 5,712,145). This approximately 3000 amino acid polyprotein contains, from the amino terminus to the carboxy terminus, a nucleocapsid protein (C), envelope proteins (E1 and E2) and several non-structural proteins (NS1, 2, 3, 4a, 5a and 5b). NS3 is an approximately 68 kda protein, encoded by approximately 1893 nucleotides of the HCV genome, and has two distinct domains: (a) a serine protease domain consisting of approximately 200 of the N-terminal amino acids; and (b) an RNA-dependent ATPase domain at the C-terminus of the protein. The NS3 protease is considered a member of the chymotrypsin family because of similarities in protein sequence, overall three-dimensional structure and mechanism of catalysis. Other chymotrypsin-like enzymes are elastase, factor Xa, thrombin, trypsin, plasmin, urokinase, tPA
and PSA. The HCV NS3 serine protease is responsible for proteolysis of the polypeptide (polyprotein) at the NS3/NS4a, NS4a/NS4b, NS4b/NSSa and NSSa/NSSb junctions and is thus responsible for generating four viral proteins during viral replication. This has made the HCV NS3 serine protease an attractive target for antiviral chemotherapy. The inventive compounds can inhibit such protease. They also can modulate the processing of hepatitis C
virus (HCV) polypeptide.
It has been determined that the NS4a protein, an approximately 6 kda polypeptide, is a co-factor for the serine protease activity of NS3.
Autocleavage of the NS3iNS4a junction by the NS3/NS4a serine protease occurs intramolecularly (i'e., cis) while the other cleavage sites are processed intermolecularly (i.e.. traps).
Analysis of the natural cleavage sites for HCV protease revealed the presence of cysteine at P1 and serine at P1' and that these residues are strictly conserved in the NS4alNS4b, NS4b/NSSa and NSSa/NS5b junctions.
The NS3/NS4a junction contains a threonine at P1 and a serine at P1'. The Cys-~Thr substitution at NS3/NS4a is postulated to account for the requirement of cis rather than traps processing at this junction. See, e.~c ., Pizzi et al. (1994) Proc. Natl. Acad. Sci. ~USA~ 91:888-892, Failla et al.
(1996) Foldinq_& Design 1:35-42. The NS3/NS4a cleavage site is also more tolerant of mutagenesis than the other sites. See, e.g_, Kollykhalov et al.
(1994) J. Virol. 68:7525-7533. It has also been found that acidic residues in the region upstream of the cleavage site are required for efficient cleavage.
See, e.a., Komoda et al. (1994) J. Virol. 68:7351-7357.
Inhibitors of HCV protease that have been reported include antioxidants (see, International Patent Application Publication No. WO
98/14181 ), certain peptides and peptide analogs (see, International Patent Application Publication No. WO 98/17679, Landro et al. (1997) Biochem.
36:9340-9348, Ingallinella et al. (1998) Biochem. 37:8906-8914, Llinas-Brunet et al. (1998) Bioora. Med. Chem. Lett. 8:1713-1718), inhibitors based on the 70-amino acid polypeptide eglin c (Martin et al. (1998) Biochem.
37:11459-11468, inhibitors affinity selected from human pancreatic secretory trypsin inhibitor (hPSTI-C3) and minibody repertoires (MBip) (Dimasi et al.
(1997) J. Virol. 71:7461-7469), cVHE2 (a "camelized" variable domain antibody fragment) (Martin et a1.(1997) Protein Ena. 10:607-614), and a1-antichymotrypsin (ACT) (Elzouki et al. (1997) J. Hepat. 27:42-28). A
ribozyme designed to selectively destroy hepatitis C virus RNA has recently been disclosed (see, BioVllorld Today 9 217 : 4 (November 10, 1998)).
Reference is also made to the PCT Publications, No. WO 98/17679, published April 30, 1998 (Vertex Pharmaceuticals Incorporated); WO
98/22496, published May 28, 1998 (F. Hoffmann-La Roche AG); and WO
99/07734, published February 18, 1999 (Boehringer Ingelheim Canada Ltd.).
HCV has been implicated in cirrhosis of the liver and in induction of hepatocellular carcinoma. The prognosis for patients suffering from HCV
infection is currently poor. HCV infection is more difficult to treat than other forms of hepatitis due to the lack of immunity or remission associated with ,HCV infection. Current data indicates a less than 50% survival rate at four years post cirrhosis diagnosis. Patients diagnosed with localized resectable hepatocellular carcinoma have a five-year survival rate of 10-30%, whereas those with localized unresectable hepatocellular carcinoma have a five-year survival rate of less than 1 %.
Reference is made to WO 00/59929 (US 6,608,027, Assignee:
Boehringer Ingelheim (Canada) Ltd.; Published October 12, 2000) which discloses peptide derivatives of the formula:
H
N~A

~ Ri .,ff...

Reference is made to A. Marchetti et al, Synleft, S1, 1000-1002 (1999) describing the synthesis of bicylic analogs of an inhibitor of HCV NS3 protease. A compound disclosed therein has the formula:
H O
N' ~
v 'O H
1 sH
COOH
Reference is also made to W. Han et al, Bioorganic & Medicinal Chem.
Letf, (2000) 10, 711-713, which describes the preparation of certain a-ketoamides, a-ketoesters and a-diketones containing allyl and ethyl functionalities.
Reference is also made to WO 00/09558 (Assignee: Boehringer Ingelheim Limited; Published February 24, 2000) which discloses peptide derivatives of the formula:
~R2 H
H3C A2\ / N R
A1 \ H
H

O N
H
O
where the various elements are defined therein. An illustrative compound of that series is:

~CH3 O
Reference is also made to WO 00/09543 (Assignee: Boehringer Ingelheim Limited; Published February 24, 2000) which discloses peptide derivatives of the formula:
~Rs A~
.O
R5 R4 ., O
R6~ r H
I
O
where the various elements are defined therein. An illustrative compound of that series is:

H3C CH3 .' HsC.%~ ~ N
H3C O H ~ , \\
H ~ \ICHz O OH
O~N
H
O
Reference is also made to U.S. 6,608,027 (Boehringer lngelheim, Canada) which discloses NS3 protease inhibitors of the type:
R21 ~ W R22 i i O
O N~ ~A
R~
R~~ O
R4 ,,D...
wherein the various moieties are defined therein.
Current therapies for hepatitis C include interferon-a (INFa) and combination therapy with ribavirin and interferon. See, e.a., Beremguer et al.
(1998) Proc. Assoc. Am. Ph sib 110 2 :98-112. These therapies suffer from a low sustained response rate and frequent side effects. See, e.a., Hoofnagle et al. (1997) N. Enal. J. Med. 336:347. Currently, no vaccine is available for HCV infection.
Reference is further made to WO 01/74768 (Assignee: Vertex Pharmaceuticals Inc) published October 11, 2001, which discloses certain compounds of the following general formula (R is defined therein) as NS3-serine protease inhibitors of Hepatitis C virus:

A specific compound disclosed in the afore-mentioned WO 01/74768 has the following formula:
N H3C CHa CH3 O
N~ O
O O O
O ~ N CH, 'H
O
O
\N
O
PCT Publications WO 01/77113; WO 01/081325; WO 02/08198; WO
02/08256; WO 02/08187; WO 02/08244; WO 02/48172; WO 02/08251; and pending U.S. patent application, Serial No. 10/052,386, filed January 18, 2002, disclose various types of peptides and/or other compounds as NS-3 serine protease inhibitors of hepatitis C virus. The disclosures of those applications are incorporated herein by reference thereto.
There is a need for new treatments and therapies for HCV infection.
There is a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of hepatitis C.
There is a need for methods of treatment or prevention or amelioration of one or more symptoms of hepatitis C.
There is a need for methods for modulating the activity of serine proteases, particularly the HCV NS3/NS4a serine protease, using the compounds provided herein.
There is a need for methods of modulating the processing of the HCV
polypeptide using the compounds provided herein.

Summar~of the Invention In its many embodiments, the present invention provides a novel class of inhibitors of the HCV protease, pharmaceutical compositions containing one or more of the compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment or prevention of HCV or amelioration of one or more of the symptoms of hepatitis C using one or more such compounds or one or more such formulations. Also provided are methods of modulating the interaction of an HCV polypeptide with HCV protease. Among the compounds provided herein, compounds that inhibit HCV NS3/NS4a serine protease activity are preferred. The present invention discloses compounds, or enantiomers, stereoisomers, rotamers, tautomers, diastereomers or racemates of said compounds, or a pharmaceutically acceptable salt, solvate or ester of said compounds, said compounds having the general structure shown in structural Formula 1:
M A
L E
N R~
N
Y N O
~O

Formula I
wherein:
R~ is H, OR8, NR9R~°, or CHR9R~°, wherein R8, R9 and R~° can be the same or different, each being independently selected from the group consisting of H, alkyl-, alkenyl-, alkynyl-, aryl-, heteroalkyl-, heteroaryl-, cycloalkyl-, heterocyclyl-, arylalkyl-, and heteroarylalkyl;
A and M can be the same or different, each being independently selected from R, OR, NHR, NRR', SR, S02R, and halo; or A and M are connected to each other such that the moiety:

M\L E/A
shown above in Formula I forms either a three, four, six, seven or eight-membered cycloalkyl, a four to eight-membered heterocyclyl, a six to ten-membered aryl, or a five to ten-membered heteroaryl;
E is C(H) or C(R);
L is C(H), C(R), CH2C(R), or C(R)CH2;
R, R', R2, and R3 can be the same or different, each being independently selected from the group consisting of H, alkyl-, alkenyl-, alkynyl-, cycloalkyl-, heteroalkyl-, heterocyclyl-, aryl-, heteroaryl-, (cycloalkyl)alkyl-, (heterocyclyl)alkyl-, aryl-alkyl-, and heteroaryl-alkyl-;
or alternately R and R' in NRR' are connected to each other such that NRR' forms a four to eight-membered heterocyclyl;
and Y is selected from the following moieties:
R1g ~ R16 ~ R16 R1~O~G~~ R15~G~G~~ R1~G~G~G$

or R1~N~G G
1s wherein G is NH or O; and R15, Rls, R17, Rls, and R19 can be the same or different, each being independently selected from the group consisting of H, alkyl, heteroalkyl, alkenyl, heteroalkenyl, alkynyl, heteroalkynyl, cycloalkyl, heterocyclyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, or alternately, (i) either R15 and R16 are connected to each other to form a four to eight-membered cyclic structure, or R1~ and R1g are connected to each other to form a four to eight-membered cyclic structure, and (ii) likewise, independently, R17 and R1$ are connected to each other to form a three to eight-membered cycloalkyl or heterocyclyl;
wherein each of said alkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl can be unsubstituted or optionally independently substituted with one or more moieties selected from the group consisting of: hydroxy, alkoxy, aryloxy, thin, alkylthio, arylthio, amino, amido, alkylamino, arylamino, alkylsulfonyl, arylsulfonyl, sulfonamido, alkylsulfonamido, arylsulfonamido, alkyl, aryl, heteroaryl, keto, carboxy, carbalkoxy, carboxamido, alkoxycarbonylamino, alkoxycarbonyloxy, alkylureido, arylureido, halo, cyano, and nitro.
5 The above-noted statement "A and M are connected to each other such that the moiety:
M\ /A
L-E
shown above in Formula I forms either a three, four, six, seven or eight-membered cycloalkyl, a four to eight-membered heterocyclyl, a six to ten-10 membered aryl, or a five to ten-membered heteroaryl" can be illustrated in a non-limiting matter as follows. Thus, for example, iri the case where A and M
are connected such that the moiety:
M\L E~A
shown above in Formula I forms a six -membered cycloalkyl (cyclohexyl), Formula I can be depicted as:
N R~
H
Y N
O

One with ordinary skill in the art will appreciate that similar depictions for Formula I can be arrived at when A and M shown above in the moiety:
M\L E/A

are connected to form a three, four, seven or eight-membered cycloalkyl, a four to eight-membered heterocyclyl, a six to ten-membered aryl, or a five to ten-membered heteroaryl.
The statement above: "alternately, (i) either R~5 and R~6 are connected to each other to form a four to eight-membered cyclic structure, or R~5 and R'9 are connected to each other to form a four to eight-membered cyclic structure, and (ii) likewise, independently, R~7 and R'$ are connected to each other to form a three to eight-membered cycloalkyl or heterocyclyl" means the following possibilities: (i) that R~5 and R~6 are connected to form a cyclic , structure while R'5 and R~9 are not; (ii) that R~5 and R~9 are connected to form a cyclic structure while R~5 and R'6 are not; and that (iii) R~' and R~$ are independently connected to form a cyclic structure, irrespective of whether the possibilities in (i) and (ii) exist or not.
In the above-noted definitions of R, R', R2, and R3 preferred alkyl is made of one to ten carbon atoms, preferred alkenyl or alkynyl is made of two to ten carbon atoms, preferred cycloalkyl is made of three to eight carbon atoms, and preferred heteroalkyl, heteroaryl or heterocycloalkyl has one to six oxygen, nitrogen, sulfur, or phosphorus atoms.
The compounds represented by Formula i, by themselves or in combination with one or more other suitable agents disclosed herein, can be useful for treating diseases such as, for example, HCV, HIV, AIDS (Acquired Immune Deficiency Syndrome), and related disorders, as well as for modulating the activity of hepatitis C virus (HCV) protease, preventing HCV, or ameliorating one or more symptoms of hepatitis C. Such modulation, treatment, prevention or amelioration can be done with the inventive compounds as well as with pharmaceutical compositions or formulations comprising such compounds. Without being limited to theory, it is believed that the HCV protease may be the NS3 or NS4a protease. The inventive compounds can inhibit such protease. They can also modulate the processing of hepatitis C virus (HCV) polypeptide.

Detailed Descriation In an embodiment, the present invention discloses compounds which are represented by structural Formula 1 or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are as defined above.
in another embodiment, R' is NR9R'°, and R9 is H, R'° is H, or R'4 wherein R'4 is H, alkyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, alkyl-aryl, alkyl-heteroaryl, aryl-alkyl, alkenyl, alkynyl or heteroaryl-alkyl.
In another embodiment, R'4 is selected from the group consisting of:
,~xiH ,dime , yl 4 , ~~ ~ ~~~1_5 F
~~~~ ~ ~ ~ ~ , 1_3 1-3 1-3 \F
1_4 , 1_4 OH OH
~~~1-3 , -OH, ~-OMe, ~~OMe ~ ~~OH
Me Me Me ~ I , ' I
Me ~ ' \ \\~N
N
~~~~~N ' ,N ~. ~ I
-~\~ , \ I , N
Me S S
I / ' ~ ~> > ~ ' and 1-3 N ~ 1-3 \
In another embodiment, R2 is selected from the group consisting of the following moieties:

I
CHs , ~ , , , CHs CHs ' , , , , CH2F CHs CHs F F
F ~ F'\F F FCJ , CFs f F ' CHs ' s F .~'~"
F ' , F F
F F
F
NC ' F ' / , F , FsC ' F
~ ' O S
, , " 0-3 ' F OH
\O 'S(O)o-z ' CHs ' ~ ' CHs ~ S~O)o-2 CHs CHs , F
F
, , , , , F F O " n = 0-3 n = 0-3 n = 0-3 F F F and , , S ~ F

In another embodiment, R3 is selected from the group consisting of:
~ CH3 _O
CH3 'CH3 , CH3~CH3 , CH3 ~ CH3\' CH3 CH3 ' i / ' H3C SCH3 , ,~~"' """" ~ C02Et CH3\I
J
0_4 , ~ / ~ / , ~ , , HsC S , O F F

, ' ' / F

F F
F
) 0-3 ' ' , CFa S COOH
i~

CH3 O"CH3 CH3 COR3~ COR3~ CH3~ 3Hs , Me .nnv Me / /\

NneV NnN
NnN NNV
Me R3~ NHR32 ' CF

CH3\I ~
F3C ' ~ ' SBn 1 HO"CH3 COOH H3C ' WW
.MN JWtf OJ , ~COOH , ' ~ J ' CH3' CHCH3 ~ S~ O
3 ,M"!
Me , OH Me Me 0-3 F3C CF3 Ww CI CI Me~Me F F
' . and H3C~CH3 Rsi CH

wherein R31 is OH or O-alkyl; and 5 R32 is H, C(O)CH3, C(O)OtBu or C(O)N(H)tBu.
In an additional embodiment, R3 is selected from the group consisting of the following moieties:
Ww Ww Ww ,~ uuw CH "CN3 , CH3' ' 'CH3 CH3~CH3 CN3 CH3 1 R31 ' CH ' 0-4 ,~yyt yy~ WW. W1M JNM

f 1 7 f J
O
CHg~CHg ' ' 0 3 ' iS\ ' CH3 OH Me Me O O
' ' ' CF3 C02H C02H
\ / CI CI
CH3 ~CF3 ~
Me' I 'CF3 and Me \ ~ F F F F
In another embodiment, Y is selected from the following moieties:
R16 ~ R16 ~ R16 R1~O~N~~as R15~O~N~~ R150~O~N~~
R17J~R1s R1/~\R1fi R1~/\R1s II H
or R15N~0 N
1s R1s R17 R
wherein_R15, R16, R17, Rls, and R19 can be the same or different, each being independently selected from the group consisting of H, alkyl, heteroalkyl, alkenyl, heteroalkenyl, alkynyl, heteroalkynyl, cycioalkyl, heterocyclyl, aryl, and heteroaryl, or alternately, (i) either R1~ and R16 are connected to form a four to eight-membered cyclic structure, or R15 and R19 are connected to form a four to eight-membered cyclic structure, and (ii) likewise, independently, R17 and R1$ are connected to form a three to eight-membered cycloalkyl or heterocyclyl;
wherein each of said alkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl can be unsubstituted or optionally independently substituted with one or more moieties selected from the group consisting of: hydroxy, alkoxy, aryloxy, thio, alkylthio, arylthio, amino, amido, alkylamino, arylamino, alkylsulfonyl, arylsulfonyl, sulfonamido, alkylsulfonamido, arylsulfonamido, keto, carboxy, carbalkoxy, carboxamido, alkoxycarbonylamino, alkoxycarbonyloxy, alkylureido, arylureido, halo, cyano, and nitro.
In an additional embodiment, the moiety:
,~''~N~~
R~7/~R~s is selected from the group consisting of:
H H
~~N\~ ~ , H
'st'. N I ,.rs' N ~ ,~'''~ N ~ ,,r~'~ N
'~.~-~Ny ~ Me ~ , , 0_3 ~ 0_3 , H
~''s N ''~ N\~ '~ N\~ ~ N
's~' ~ , N '~'' N~ '''.' N\ '~ N\~ ',~' N~
y 0_4 , , ~ ' F F
H
N, e~ ~ and O
N Ys2 , O ' O
Ysa wherein Y32 is selected from the group consisting of:
Hi~' ' O~~', ~0~~-, iS~~~, ~N~ and ~ a ~ o ~ H ~ o R~6 is selected from H, methyl, phenyl, benzyl; and R~5 and R~9 maybe the same or different, each being independently selected from the following:

H~~'~C' , Me~~' ~ ~'~rt , /~/~'ir' ~~ , 'r. , .1_5 )n=1-5 , ~. ~~. , ~ ! ~. and , , or alternately, the moiety:
R15N~~.

is selected from the following moieties:
N~~z, ~N'~ ~N~''~r.
0-3 Ys2'N
~N~~. ~N~~
S J Or ~s,.s~
In an additional embodiment, R16 is H.
In another embodiment, the moiety:
M A
L-E
N
O
O
is selected from the following structures:

alkyl ~O aryl ~O
O , O
~N~ ,~N~
COI O
Me H O Me Me Me O ~Me OH Me OH
I ~H , I H , I H
~N ~N ~N
O O O
CI~CI ,F~.F B ~Br O
I ' ~N I ~N ,r~N
p ~ I
O
Me ~Me O
O O
,~ N
O
Me O ~Me H H OH O -'tO
H ~ p1 H ' I H ' I
~N j N ' N ~N
O O O O
~0-4 CF3 C ~/I
O O
N ~/' ~N~ ~N~ ~ O ~ N II
O O ~O w0 O

nne ,~Me O
I > O , O ,, ~N~ ~N ~N
p o I
O
Me 1/Me ~O
O , ~ , N N II ~N~
O O
O
n o s os s o ~N ' ~N ' ' N II
0 ~ O
Me Me O ,Me ' O ' O
~N ~N~ ~N I
p J~OT~ O
Me Me Me Me O Me Me f ~ ~ , ' N \l N l l \\ N I
O O O O
~O ~ \ O
I . , I
O O ~ , N I ~N~ ~N~
O COI O
O H CI
OS O ~ N w ~ \ O
\ NH ~ CI~
O ~ O
' I and ,~N ~N~ N I
Ip O O
In an additional embodiment, the moiety:

M A

L-E

O
O
is selected from the following structures:
alkyl ~O aryl ~O
O , O
~N~ ~N~
COI I ~O
Me ~ ~.Me H O
M ~Me O H O ,O
O
, N i O N O N O
CI
Br SCI
,F~F ~Br O O
O ,., I , I
N I ~N ~N
O O I
O
Me n -~' Me S S
O~ O O
O , ~N~ , ~N
~N O I
I O
O
Me Ma Me Me~O
O , ~N~ ~ o N ~ ,~N
O
O O
O
PhoS:O Ph~NH
NH
O
O O , I ' , N II ~N
0 ~ o CI
O
~I N
~N~ ~ \~ ~ N\ II and N II
O ~O ~O O ~O O
In a still additional embodiment, the moiety:
M A
L E
N
O
O
is selected from the following structures:
CI~CI F~F
N II , N II , N II
~O O ~O O d 'O O
Br~Br N
N~ ~ and ~N~~.
O ~00 ~0''0 In a further additional embodiment, R~ is NHR~4, where R'4 is selected from the group consisting of:
,Me ~~ , ~~ ~ ~~) 1_5 '~rx.~ ' ~ ~ 1 _4 1 _4 , F
i , ~~~ , ~~ ~ ~~(~ , 1_3 1_3 1_3 wF
F 1_q. , 1-4 , -OH, ~-OMe, ~~OMe , ~~OH , Me Me Me ~~OH '~x~ ~ '~,~ iN '~
Me ~ ~N I ' \ I ~ ~N
~I
N \ I , ~N
Me N> > ~ ' \ and ~ \ I
1-3 ~ 1-3 ~ 1-3 ' R2 is selected from the group consisting of the following moieties:
CHs , CHs , , ~ , , CHs > > , CHs CHs F F '"""' ~ , F ~ F' \F F F CJ , CH2F CFs F ' CHs ' s CHF2 F
F ' I , , ' ~ ~ F F ' F F
F
NC ' F ' / , F , FsC ' F
' O ~ S
0-3 ~ ' ' F OH

~S~~)0-2 ' CH3 ' ~ ' CH3 , S~C)o-2 CH3 CH3 , '~ ~.. '~- F
F
U , , F F ~ n = 0-3 M n = 0-3 F F F and S ~' F
R3 is selected from the group consisting of the following moieties:
"""". .""", .""", ."""" """"
CH3 'CH3 , CH3' I 'CH3 CH3~CH3 CH3 CH3 ' R31 ' CH ' 0-4 W W, JW V. JWV ,~,~,N~ W W, ' ' \

O
0-3 ~ $
CH3 CH3 H3 , OH , Me Me ' O~ ip CI Cl CF3 ~
Me' I 'CF3 and y- > > Me F F F F
, Y is selected from the group consisting of:

R16 0 R16 ~ R16 R1~O~G~.~ R15~O~G~~ R1~O~O~G~~
R17~R18 R17//~~(~18 R17 R18 or R15N~0 1s R19 R17 [~
wherein G = NH, and the moiety, ,.~''~~N~~
R17/~Rls is selected from the group consisting of:

N~
,s',' N ,''~' N ~~ ,s's N ~~s '~ N \~
~r y ~ ~ , , '~,,~N~~ Me , 0-3 , 0_3 , ~ , , H
N ~''~ N~ ~ N~~ '~ N
, , , N~ ~ N~~ ~,''r N
0-4 ' ' ' F F
ss's N\~ ~s1' N~~s r~,.r N '~ N~~ ~ N~
' N. ~~ ~ and O
N Ys2 , O ' O
Ys2 R16 = H, and R1~ and R19 can be the same or different, each being independently 10 selected from the following:

, , ~n=1-5 ~n=1-5 ~~. ~~. , W ( ~. and , or alternately, the moiety:
R'sN~~.

is represented by one of the following moieties, N~'~ ~N'~- ~N~~r.
J 0-3 y32' N ~ ~J
~N~~. N~~.
Or ~ si and the moiety:
is:

Me / ~ O O ,.CF3 ,,~ Me ~'' O , O ~ ,- O ~ ~N~ , ~N ~N~ ~N O
p O O
F~ F
y e,0 alkyl w0 O
alkyI~S~NH O
~N~
N ' o I
O N N~ O
~w O ~O
~O O
O~ e0 Br~Br aryl\O CI~CI
aryI~S~NN O . O
O ' , I , I >
. ~w O ~N~ ~N~
O O O
O
Me Me ~ O~ CI
N ~ O o or ~N ~ O
I_ O O ~O ~o ~O
Yet another embodiment of the invention discloses compounds shown in Table 1, Table 1A, Table 2 and Table 3 later in this Description. Also shown in the Tables are the biological activities of several inventive compounds (as Ki* values).
In an additional embodiment, this invention discloses the following compounds in Table 4:
Table 4 .. p NNx N
N ~ /~ II
p p p p p p p\ JNH
p\ 'NH
o......... ~ NH
~NH
O

In an additional embodiment, the present invention discloses the following compounds in Table 5:

~p~oi As used above, and throughout this disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:
"Pafiient" includes both human and animals.
"Mammal" means humans and other mammalian animals.
"Alkyl" means an aliphatic hydrocarbon group which may be straight or branched and comprising about 1 to about 20 carbon atoms in the chain.
Preferred alkyl groups contain about 1 to about 12 carbon atoms in the chain.
More preferred alkyl groups contain about 1 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkyl chain. "Lower alkyl" means a group having about 1 to about 6 carbon atoms in the chain which may be straight or branched. The term "substituted alkyl" means that the alkyl group may be substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, aryl, cycloalkyl, cyano, hydroxy, alkoxy, alkylthio, amino, -NH(alkyl), -NH(cycloalkyl), -N(alkyl)2, -N(alkyl)2, carboxy and -C(O)O-alkyl. Non-limiting examples of suitable alkyl groups include methyl, ethyl, n-propyl, isopropyl and t-butyl.
"Alkenyl" means an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be straight or branched and comprising aboufi 2 to about 15 carbon atoms in the chain. Preferred alkenyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkenyl chain. "Lower alkenyl" means about 2 to about 6 carbon atoms in the chain which may be straight or branched. The term "substituted alkenyl" means that the alkenyl group may be substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl. aryl, cycloalkyl, cyano, alkoxy and -S(alkyl). Non-limiting examples of suitable alkenyl groups include ethenyl, propenyl, n-butenyl, 3-methylbut-2-enyl, n-pentenyl, octenyl and decenyl.

"Alkynyl" means an aliphatic hydrocarbon group containing at least one carbon-carbon triple bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. Preferred alkynyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkynyl chain. "Lower alkynyl" means about 2 to about 6 carbon atoms in the chain which may be straight or branched. Non-limiting examples of suitable alkynyl groups include ethynyl, propynyl, 2-butynyl and 3-methylbutynyl. The term "substituted alkynyl" means that the alkynyl group may be substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of alkyl, aryl and cycloalkyl.
"Aryl" means an aromatic monocyclic or multicyclic ring system comprising about 6 to about 14 carbon atoms, preferably about 6 to about 10 carbon atoms. The aryl group can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined herein. Non-limiting examples of suitable aryl groups include phenyl and naphthyl.
"Heteroaryl" means an aromatic monocyclic or multicyclic ring system comprising about 5 to about 14 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the ring atoms is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination.
Preferred heteroaryls contain about 5 to about 6 ring atoms. The "heteroaryl"
can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein. The prefix aza, oxa or this before the heteroaryl root name means that at least a nitrogen, oxygen or sulfur atom respectively, is present as a ring atom. A nitrogen atom of a heteroaryl can be optionally oxidized to the corresponding N-oxide. Non-limiting examples of suitable heteroaryls include pyridyl, pyrazinyl, furanyl, thienyl, pyrimidinyl, pyridone (including N-substituted pyridones), isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, pyrazoiyl, furazanyl, pyrrolyl, pyrazolyl, triazolyl, 1,2,4-thiadiazolyl, pyrazinyl, pyridazinyl, quinoxalinyl, phthalazinyl, oxindolyl, imidazo[1,2-a]pyridinyl, imidazo[2,1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinolinyl, imidazolyl, thienopyridyl, quinazolinyl, thienopyrimidyl, pyrrolopyridyl, imidazopyridyl, isoquinolinyl, benzoazaindolyl, 1,2,4-triazinyl, benzothiazolyl and the like.
The term "heteroaryl" also refers to partially saturated heteroaryl moieties such as, for example, tetrahydroisoquinolyl, tetrahydroquinolyl and the like.
"Aralkyl" or "arylalkyl" means an aryl-alkyl- group in which the aryl and alkyl are as previously described. Preferred aralkyls comprise a Power alkyl group. Non-limiting examples of suitable aralkyl groups include benzyl, 2-phenethyl and naphthalenylmefihyl. The bond to the parent moiety is through the alkyl.
"Alkylaryl" means an alkyl-aryl- group in which the alkyl and aryl are as previously described. Preferred alkylaryls comprise a lower alkyl group. Non-iimiting example of a suitable alkylaryl group is tolyl. The bond to the parent moiety is through the aryl.
"Cycloalkyl" means a non-aromatic mono- or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably aboufi 5 to about 10 carbon atoms. Preferred cycloalkyl rings contain about 5 to about 7 ring atoms. The cycloalkyl can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined above. Non-limiting examples of suitable monocyclic cycloaikyls include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. Non-limiting examples of suitable multicyclic cycloalkyls include 1-decalinyl, norbornyl, adamantyl and the like, as well as partially saturated species such as, for example, indanyl, tetrahydronaphthyl and the like.
"Halogen" or "halo" means fluorine, chlorine, bromine, or iodine.
Preferred are fluorine, chlorine and bromine.
"Ring system substituent" means a substituent attached to an aramatic or non-aromatic ring system which, for example, replaces an available hydrogen on the ring system. Ring system substituents may be the same or different, each being independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, alkylaryl, heteroaralkyl, heteroarylalkenyl, heteroarylalkynyl, alkylheteroaryl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl, araikoxycarbonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylthio, arylthio, heteroarylthio, aralkylthio, heteroaralkylthio, cycloalkyl, heterocyclyl, -C(=N-CN)-NH2, -C(=NH)-NH2, -C(=NH)-NH(alkyl), Y~Y2N-, Y~Y2N-alkyl-, Y~Y2NC(O)-, Y~Y2NS02- and -S02NY~Y2, wherein Y~ and Y2 can be the same or different and are independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, and aralkyl. "Ring system substituent" may also mean a single moiety which simultaneously replaces two available hydrogens on two adjacent carbon atoms (one H on each carbon) on a ring system. Examples of such moiety are methylene dioxy, ethylenedioxy, -C(CH3)2- and the like which form moieties such as, for example:
~--o o and "Heterocyclyl" means a non-aromatic saturated monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. There are no adjacent oxygen and/or sulfur atoms present in the ring system. Preferred heterocyclyls contain about 5 to about 6 ring atoms. The prefix aza, oxa or thia before the heterocyclyl roof name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom. Any-NH in a heterocyclyl ring may exist protected such as, for example, as an -N(Boc), -N(CBz), -N(Tos) group and the like;
such protections are also considered part of this invention. The heterocyclyl can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein. The nitrogen or sulfur atom of the heterocyclyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Non-limiting examples of suitable monocyclic heterocyclyl rings include piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, lactam, lactone, and the like.
It should be noted that in hetero-atom containing ring systems of this invention, there are rio hydroxyl groups on carbon atoms adjacent to a N, O or S, as well as there are no N or S groups on carbon adjacent to another heteroatom. Thus, for example, in the ring:

N
H
there is no -OH attached directly to carbons marked 2 and 5.

5 It should also be noted that tautomeric forms such as, for example, the moieties:
N O
H and N OH
are considered equivalent in certain embodiments of this invention.
"Alkynylalkyl" means an alkynyl-alkyl- group in which the alkynyl and 10 alkyl are as previously described. Preferred alkynylalkyls contain a lower alkynyl and a lower alkyl group. The bond to the parent moiety is through the alkyl. Non-limiting examples of suitable alkynylalkyl groups include propargylmethyl.
"Heteroaralkyl" means a heteroaryl-alkyl- group in which the heteroaryl 15 and alkyl are as previously described. Preferred heteroaralkyls contain a lower alkyl group. Non-limiting examples of suitable aralkyl groups include pyridylmethyl, and quinolin-3-ylmethyl. The bond to the parent moiety is through the alkyl.
"Hydroxyalkyl" means a HO-alkyl- group in which alkyl is as previously 20 defined. Preferred hydroxyalkyls contain lower alkyl. Non-limiting examples of suitable hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl.
"Acyl" means an H-C(O)-, alkyl-C(O)- or cycloalkyl-C(O)-, group in which the various groups are as previously described. The bond to the parent moiety is through the carbonyl. Preferred acyls contain a lower alkyl. Non-25 limiting examples of suitable acyl groups include formyi, acetyl and propanoyl.
"Aroyl" means an aryl-C(O)- group in which the aryl group is as previously described. The bond to the parent moiety is through the carbonyl.
Non-limiting examples of suitable groups include benzoyl and 1- naphthoyl.

"Alkoxy" means an alkyl-O- group in which the alkyl group is as previously described. Non-limiting examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy and n-butoxy. The bond to the parent moiety is through the ether oxygen.
"Aryloxy" means an aryl-O- group in which the aryl group is as previously described. Non-limiting examples of suitable aryloxy groups include phenoxy and naphthoxy. The bond to the parent moiety is through the ether oxygen.
"Aralkyloxy" means an aralkyl-O- group in which the aralkyl group is as previously described. Non-limiting examples of suitable aralkyloxy groups include benzyloxy and 1- or 2-naphthalenemethoxy. The bond to the parent moiety is through the ether oxygen.
"Alkylthio" means an alkyl-S- group in which the alkyl group is as previously described. Non-limiting examples of suitable alkyithio groups include methylthio and ethylthio. The bond to the parent moiety is through the sulfur.
"Arylthio" means an aryl-S- group in which the aryl group is as previously described. Non-limiting examples of suitable arylthio groups include phenylthio and naphthylthio. The bond to the parent moiety is through the sulfur.
"Aralkylthio" means an aralkyl-S- group in which the aralkyl group is as previously described. Non-limiting example of a suitable aralkylthio group is benzylthio. The bond to the parent moiety is through the sulfur.
"Alkoxycarbonyl" means an alkyl-O-CO- group. Non-limiting examples of suitable alkoxycarbonyl groups include methoxycarbonyl and ethoxycarbonyl. The bond to the parent moiety is through the carbonyl.
"Aryloxycarbonyl" means an aryl-O-C(O)- group. Non-limiting examples of suitable aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl. The bond to the parent moiety is through the carbonyl.
"Aralkoxycarbonyl" means an aralkyl-O-C(O)- group. Non-limiting example of a suitable aralkoxycarbonyl group is benzyloxycarbonyl. The bond to the parent moiety is through the carbonyl.

"Alkylsulfonyl" means an alkyl-S(02)- group. Preferred groups are those in which the alkyl group is lower alkyl. The bond to the parent moiety is through the sulfonyl:
"Arylsulfonyl" means an aryl-S(OZ)- group. The bond to the parent moiety is through the sulfonyl.
The term "substituted" means that one or more hydrogens on the designated atom is replaced wifih a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. By "stable compound' or "stable structure" is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
The term "one or more" or "at least one", when indicating the number of substituents, compounds, combination agents and the like, refers to at least one, and up to the maximum number of chemically and physically permissible, substituents, compounds, combination agents and the like, that are present or added, depending on the context. Such techniques and knowledge are well known within the skills of the concerned artisan.
The term "optionally substituted" means optional substitution with the specified groups, radicals or moieties.
The term "isolated" or "in isolated form" for a compound refers to the physical state of said compound after being isolated from a synthetic process or natural source or combination thereof. The term "purified" or "in purified form" for a compound refers to the physical state of said compound after being obtained from a purificafiion process or processes described herein or well known to the skilled artisan, in sufficient purity to be characterizable by standard analytical techniques described herein or well known to the skilled artisan.
It should also be noted that any heteroatom with unsatisfied valences in the text, schemes, examples and Tables herein is assumed to have the hydrogen atoms) to satisfy the valences.

When a functional group in a compound is termed "protected", this means that the group is in modified form to preclude undesired side reactions at the protected site when the compound is subjected to a reaction. Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T. W.
Greene ef al, Protective Groups in organic Synthesis (1991 ), Wiley, New York.
When any variable (e.g., aryl, heterocycle, R2, etc.) occurs more than one time in any constituent or in Formula 1, its definition on each occurrence is independent of its definition at every other occurrence.
As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
Prodrugs and solvates of the compounds of the invention are also contemplated herein. The term "prodrug", as employed herein, denotes a compound that is a drug precursor which, upon administration to a subject, undergoes chemical conversion by metabolic or chemical processes to yield a compound of Formula 1 or a salt and/or solvate thereof. A discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems (1987) 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press, both of which are incorporated herein by reference thereto.
"Solvate" means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate" encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. "Hydrate" is a solvate wherein the solvent molecule is HBO.

"Effiective amount" or "therapeutically effective amount" is meant to describe an amount of compound or a composition of the present invention effective in inhibiting the CDK(s) and thus producing the desired therapeutic, ameliorative, inhibitory or preventative effect.
The compounds of Formula 1 can form salts which are also within the scope of this invention. Reference to a compound of Formula 1 herein is understood to include reference to salts thereof, unless otherwise indicated.
The term "salt(s)", as employed herein, denotes acidic salts formed with inorganic andlor organic acids, as well as basic salts formed with inorganic and/or organic bases. In addition, when a compound of Formula 1 contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions ("inner salts") may be formed and are included within the term "salt(s)" as used herein. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful. Salts of the compounds of the Formula 1 may be formed, for example, by reacting a compound of Formula 1 with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization. ' Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesuifonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates,) and the like. Additionally, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl ef al, Camille G. (eds.) Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley-VCH; S. Berge et al, Journal of Pharmaceutical Sciences (1977) 66 1 1-19; P. Could, International J. of Pharmaceutics (1986) 33 201-217;
Anderson et al, The Practice of Medicinal Chemistry (1996), Academic Press, New York; and in The Orange Book (Food & Drug Administration, Washington, D.C, on their website). These disclosures are incorporated herein by reference thereto.
EXemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as 5 calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamines, t-butyl amines, and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides (e.g. methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g.
10 dimethyl, diethyl, and dibutyl sulfates), long chain halides (e.g. decyl, lauryl, and stearyl chlorides, bromides and iodides), aralkyl halides (e.g. benzyl and phenethyl bromides), and others.
All such acid salts and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts 15 are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.
Pharmaceutically acceptable esters of the present compounds include the following groups: (1 ) carboxylic acid esters obtained by esterification of the hydroxy groups, in which the non-carbonyl moiety of the carboxylic acid 20 portion of the ester grouping is selected from straight or branched chain alkyl (for example, acetyl, n-propyl, t-butyl, or n-butyl), alkoxyalkyl (for example, methoxymethyl), aralkyl (for example, benzyl), aryloxyalkyl (for example, phenoxymethyl), aryl (for example, phenyl optionally substituted with, for example, halogen, C~~alkyl, or C~_4alkoxy or amino); (2) sulfonate esters, 25 such as alkyl- or aralkylsulfonyl (for example, methanesulfonyl); (3) amino acid esters (for example, L-valyl or L-isoleucyl); (4) phosphonate esters and (5) mono-, di- or triphosphate esters. The phosphate esters may be further esterified by, for example, a C~_zo alcohol or reactive derivative thereof, or by a 2,3-di (C6_24)acyl glycerol.
30 Compounds of Formula 1, and salts, solvates, esters and prodrugs thereof, may exist in their tautomeric form (for example, as an amide or imino ether). All such tautomeric forms are contemplated herein as part of the present invention.

All stereoisomers (for example, geometric isomers, optical isomers, and the like) of the present compounds (including those of the salts, solvates and prodrugs of the compounds as well as the salts and solvates of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl).
Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The chiral centers of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations. The use of the terms "salt", "solvate"
"prodrug" and the like, is intended to equally apply to the salt, solvate and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs of the inventive compounds.
Polymorphic forms of the compounds of Formula I, and of the. salts, solvates, esters and prodrugs of the compounds of Formula I, are intended to be included in the present invention.
It is to be understood that the utility of the compounds of Formula 1 for the therapeutic applications discussed herein is applicable to each compound by itself or to the combination or combinations of one or more compounds of Formula 1 as illustrated, for example, in the next immediate paragraph. The same understanding also applies to pharmaceutical compositions) comprising such compound or compounds and methods) of treatment involving such compound or compounds.
The compounds according to the invention can have pharmacological properties; in particular, the compounds of Formula 1 can be inhibitors of HCV
protease, each compound by itself or one or more compounds of Formula 1 can be combined with one or more compounds selected from within Formula 1. The compounds) can be useful for treating diseases such as, for example, HCV, HIV, (AIDS, Acquired Immune Deficiency Syndrome), and related disorders, as well as for modulating the activity of hepatitis C virus (HCV) protease, preventing HGV, or ameliorating one or more symptoms of hepatitis C.
The compounds of Formula 1 may be used for the manufacture of a medicament to treat disorders associated with the HCV protease, for example, the method comprising bringing into intimate contact a compound of Formula 1 and a pharmaceutically acceptable carrier.
In another embodiment, this invention provides pharmaceutical compositions comprising the inventive compound or compounds as an active ingredient. The pharmaceutical compositions generally additionally comprise at least one pharmaceutically acceptable carrier diluent, excipient or carrier (collectively referred to herein as carrier materials). Because of their HCV
inhibitory activity, such pharmaceutical compositions possess utility in treating hepatitis C and related disorders.
in yet another embodiment, the present invention discloses methods for preparing pharmaceutical compositions comprising the inventive compounds as an active ingredient. In the pharmaceutical compositions and methods of the present invention, the active ingredients will typically be administered in admixture with suitable carrier materials suitably selected with respect to the intended form of administration, i.e. oral tablets, capsules (either solid-filled, semi-solid filled or liquid filled), powders for constitution, oral gels, elixirs, dispersible granules, syrups, suspensions, and the like, and consistent with conventional pharmaceutical practices. For example, for oral administration in the form of tablets or capsules, the active drug component may be combined with any oral non-toxic pharmaceutically acceptable inert carrier, such as lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, talc, mannitol, ethyl alcohol (liquid forms) and the like. Moreover, when desired or needed, suitable binders, lubricants, disintegrating agents and coloring agents may also be incorporated in the mixture. Powders and tablets may be comprised of from about 5 to about 95 percent inventive composition.
Suitable binders include starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, carboxymethylcellulose, polyethylene glycol and waxes. Among the lubricants there may be mentioned for use in these dosage forms, boric acid, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include starch, methylcellulose, guar gum and the like.
Sweetening and flavoring agents and preservatives may also be included where appropriate. Some of the terms noted above, namely disintegrants, diluents, lubricants, binders and the like, are discussed in more detail below.
Additionally, the compositions of the present invention may be formulated in sustained release form to provide the rate controlled release of any one or more of the components or active ingredients to optimize the 70 therapeutic efFects, i.e. HCV inhibitory activity and the like. Suitable dosage forms for sustained release include layered tablets containing layers of varying disintegration rates or controlled release polymeric matrices impregnated with the active components and shaped in tablet form or capsules containing such impregnated or encapsulated porous polymeric matrices.
Liquid form preparations include solutions, suspensions and emulsions.
As an example may be mentioned wafer or water-propylene glycol solutions for parenteral injections or addition of sweeteners and pacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration.
Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier such as inert compressed gas, e.g. nitrogen.
For preparing suppositories, a low melting wax such as a mixture of tatty acid glycerides such as cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein by stirring or similar mixing.
The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.
Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.
The compounds of the invention may also be deliverable transdermaily.
The transdermal compositions may take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.
The compounds of the invention may also be administered orally, intravenously, intranasally or subcutaneously.
The compounds of the invention may also comprise preparations which are in a unit dosage form. In such form, the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active components, e.g., an effective amount to achieve the desired purpose.
The quantity of the inventive active composition in a unit dose of preparation may be generally varied or adjusted from about 1.0 milligram to about 1,000 milligrams, preferably from about 1.0 to about 950 milligrams, more preferably from about 1.0 to about 500 milligrams, and typically from about 1 to about 250 milligrams, according to the particular application. The actual dosage employed may be varied depending upon the patient's age, sex, weight and severity of the condition being treated. Such techniques are well known to those skilled in the art.
Generally, the human oral dosage form containing the active ingredients can be administered 1 or 2 times per day. The amount and frequency of the administration will be regulated according to the judgment of the attending clinician. A generally recommended daily dosage regimen for oral administration may range from about 1.0 milligram to about 1,000 milligrams per day, in single or divided doses.
Some useful terms are described below:
Capsule - refers to a special container or enclosure made of methyl cellulose, polyvinyl alcohols, or denatured gelatins or starch for holding or containing compositions comprising the active ingredients. Hard shell capsules are typically made of blends of relatively high gel strength bone and pork skin gelatins. The capsule itself may contain small amounts of dyes, opaquing agents, plasticizers and preservatives.
Tablet- refers to a compressed or molded solid dosage form containing the active ingredients with suitable diluents. The tablet can be prepared by compression of mixtures or granulations obtained by wet granulation, dry granulation or by compaction.

Oral gel- refers to the active ingredients dispersed or solubilized in a hydrophillic semi-solid matrix.
Powder for constitution refers to powder blends containing the active ingredients and suitable diluents which can be suspended in water or juices.
5 Diluent - refers to substances that usually make up the. major portion of the composition or dosage form. Suitable diluents include sugars such as lactose, sucrose, mannitol and sorbitol; starches derived from wheat, corn, rice and potato; and celluloses such as microcrystalline cellulose. The amount of diluent in the composition can range from about 10 to about 90% by weight 10 of the total composition, preferably from about 25 to about 75%, more preferably from about 30 to about 60% by weight, even more preferably from about 12 to about 60%.
Disintegrant - refers to materials added to the composition to help ifi break apart (disintegrate) and release the medicaments. Suitable 15 disintegrants include starches; "cold water soluble" modified starches such as sodium carboxymethyl starch; natural and synthetic gums such as locust bean, karaya, guar, tragacanth and agar; cellulose derivatives such as methylcellulose and sodium carboxymethylcellulose; microcrystalline celluloses and cross-linked microcrystalline celluloses such as sodium 20 croscarmeliose; alginates such as alginic acid and sodium alginate; clays such as bentonites; and effervescent mixtures. The amount of disintegrant in the composition can range from about 2 to about 15% by weight of the composition, more preferably from about 4 to about 10% by weight.
Binder - refers to substances that bind or "glue" powders together and 25 make them cohesive by forming granules, thus serving as the "adhesive" in the formulation. Binders add cohesive strength already available in the diluenfi or bulking agent. Suitable binders include sugars such as sucrose; starches derived from wheat, corn rice and potato; natural gums such as acacia, gelatin and tragacanth; derivatives of seaweed such as alginic acid, sodium 30 alginate and ammonium calcium alginate; cellulosic materials such as methylcellulose and sodium carboxymethylcellulose and hydroxypropylmethylcellulose; polyvinylpyrrolidone; and inorganics such as magnesium aluminum silicate. The amount of binder in the composition can range from about 2 to about 20% by weight of the composition, more preferably from about 3 to about 10% by weight, even more preferably from about 3 to about 6% by weight.
Lubricant - refers to a substance added to the dosage form to enable the tablet, granules, etc. after it has been compressed, fio release from the mold or die by reducing friction or wear. Suitable lubricants include metallic stearates such as magnesium stearate, calcium stearate or potassium stearate; stearic acid; high melting point waxes; and water soluble lubricants such as sodium chloride, sodium benzoate, sodium acetate, sodium oleate, polyethylene glycols and d'I-leucine. Lubricants are usually added at the very last step before compression, since they must be present on the surfaces of the granules and in between them and the parts of the tablet press. The amount of lubricant in the composition can range from about 0.2 to about 5%
by weight of the composition, preferably from about 0.5 to about 2%, more preferably from about 0.3 to about 1.5% by weight.
Glident - material thafi prevents caking and improve the flow characteristics of granulations, so that flow is smooth and uniform. Suitable glidents include silicon dioxide and talc. The amount of glident in the composition can range from about 0.1 % to about 5% by weight of the total composition, preferably from about 0.5 to about 2% by weight.
Coloring agents - excipients that provide coloration to the composition or the dosage form. Such excipients can include food grade dyes and food grade dyes adsorbed onto a suitable adsorbent such as clay or aluminum oxide. The amount of the coloring agent can vary from about 0.1 to about 5%
by weight of the composition, preferably from about 0.1 to about 1 %.
Bioavailability - refers to the rate and extent to which the active drug ingredient or therapeutic moiety is absorbed into the systemic circulation from an administered dosage form as compared to a standard or control.
Conventional methods for preparing tablets are known. Such methods include dry methods such as direct compression and compression of granulation produced by compaction, or wet methods or other special procedures. Conventional methods for making other forms for administration such as, for example, capsules, suppositories and the like are also well known.

Another embodiment of the invention discloses the use of the inventive compounds or pharmaceutical compositions disclosed above for treatment of diseases such as, for example, hepatitis C and the like. The method comprises administering a therapeutically effective amount of the inventive compound or pharmaceutical composition to a patient having such a disease or diseases and in need of such a treatment.
In yet another embodiment, the compounds of the invention may be used for the treatment of HCV in humans in monotherapy mode or in a combination therapy (e.g., dual combination, triple combination etc.) mode such as, for example, in combination with antivira! and/or immunomodulatory agents. Examples of such antiviral and/or immunomodulatory agents include Ribavirin (from Schering-Plough Corporation, Madison, New Jersey) and LevovirinTM (from ICN Pharmaceuticals, Costa Mesa, California), VP 50406T""
(from Viropharma, Incorporated, Exton, Pennsylvania), ISIS 14803TM (from ISIS Pharmaceuticals, Carlsbad, California), HeptazymeT"" (from Ribozyme Pharmaceuticals, Boulder, Colorado), VX 497T"" (from Vertex Pharmaceuticals, Cambridge, Massachusetts), ThymosinT"" (from SciClone Pharmaceuticals, San Mateo, California), MaxamineT"" (Maxim Pharmaceuticals, San Diego, California), mycophenolate mofetil (from Hoffman-LaRoche, Nutley, New Jersey), interferon (such as, for example, interferon-alpha, PEG-interferon alpha conjugates) and the like. "PEG-interferon alpha conjugates" are interferon alpha molecules covalently attached to a PEG molecule. Illustrative PEG-interferon alpha conjugates include interferon alpha-2a (RoferonT"", from HofFman La-Roche, Nutley, New Jersey) in the form of pegylated interferon alpha-2a (e.g., as sold under the trade name PegasysTM), interferon alpha-2b (IntronTM, from Schering-Plough Corporation) in the form of pegylated interferon alpha-2b (e.g., as sold under the trade name PEG-IntronT""), interferon alpha-2c (Berofor AIphaT"", from Boehringer Ingelheim, Ingelheim, Germany) or consensus interferon as defined by determination of a consensus sequence of naturally occurring interferon alphas (InfergenT"~, from Amgen, Thousand Oaks, California).
As stated earlier, the invention includes tautomers, rotamers, enantiomers and other stereoisomers of the inventive compounds also. Thus, as one skilled in the art appreciates, some of the inventive compounds may exist in suitable isomeric forms. Such variations are contemplated to be within the scope of the invention.
Another embodimenfi of the invention discloses a method of making the compounds disclosed herein. The compounds may be prepared by several techniques known in the art. Illustrative procedures are outlined in the following reaction schemes, The illustrations should not be construed to limit the scope of the invention which is defined in the appended claims.
Alternative mechanistic pathways and analogous structures will be apparent to those skilled in the art.
It is to be understood that while the following illustrative schemes describe the preparation of a few representative inventive compounds, suitable substitution of any of both the natural and unnatural amino acids will result in the formation of the desired compounds based on such substitution.
Such variations are contemplated to be within the scope of the invention.
For the procedures described below, the following abbreviations are used:
Abbreviations Abbreviations which are used in the descriptions of the schemes, preparations and the examples that follow are:
THF: Tetrahydrofuran DMF: N,N-Dimethylformamide EtOAc: Ethyl acetate AcOH: Acetic acid HOOBt:3-Hydroxy-1,2,3-benzotriazin-4(3H)-one EDCI: 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride NMM: N-Methylmorpholine ADDP: 1,1'-(Azodicarbobyl)dipiperidine DEAD: Diethylazodicarboxylate MeOH: Methanol EtOH: Ethanol Et20: Diethyl ether DMSO: Dimethylsulfoxide HOBt: N-Hydroxybenzotriazole PyBrOP: Bromo-tris-pyrrolidinophosphonium hexafluorophosphate DCM: Dichloromethane DCC: 1,3-Dicyclohexylcarbodiimide TEMPO: 2,2,6,6-Tetramethyl-1-piperidinyloxy Phg: Phenylglycine Chg: Cyclohexylglycine Bn: Benzyl Bzl: Benzyl Et: Ethyl Ph: Phenyl iBoc: isobutoxycarbonyl iPr: isopropyl tBu or But: tent-Butyl Boc: tert-Butyloxycarbonyl Cbz: Benzyloxycarbonyl Cp: Cylcopentyldienyl Ts: p-toluenesulfonyl Me: Methyl HATU: O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate DMAP: 4-N,N-Dimethylaminopyridine BOP: Benzotriazol-1-yl-oxy-tris(dimethylamino)hexafluorophosphate PCC: Pyridiniumchlorochromate General Schemes for Preparation of Target Compounds Compounds of the present invention were synthesized using the general schemes (Methods A-E) described below.
Method A:
Deprotection of the N-Boc functionality of 1.01 under acidic conditions provided the hydrochloride salt 1.02 which was subsepuently coupled with N-Boc-tert-leucine under peptide coupling methodology to afford 1.03. N-Boc deprotection followed by treatment with appropriate isocyanate gave the urea 1.05. Hydrolysis of the methyl ester provided the acid 1.06. Peptide coupling of the acid 1.06 with the appropriate P~-P' primary amide moiety afforded the hydroxyl amide 1.07. Oxidation (Moffatt or related process - T.T.Tidwell, Synthesis, 1990, 857; or Dess~Martin's - J. Org. Chem., 1983, 48, 4155) resulted in the target compound 1.08.
v v ~OCH3 N~OCH3 ~ ~C02CH3 ~ O N~ O
_0"O O H.rHCI ~ 0 O
1.03 1.02 1.01 v v _ N~OCH3 N~OCH3 HCLH2N~O O Ca 'N Nv 'O O
p O
1.04 1.05 v v H OH
N~OH N~N NH2 Cap'N~N~O O ~ Cap'N~N~O O O
O ~ O
1.07 1.os ,.
H O
~N NH2 N
Ca 'N N~.O O O
p O
5 1.os Method B
Peptide coupling of the acid 1.06 with the appropriate P~-P' secondary amide moiety afforded the hydroxyl amide 1.09. Oxidation (Moffatt or Dess-Martin's) 10 resulted in the target compound 1.10.

V ' V
H OH H
N~OH N~N N
Cap N N~O O ' Cap N N~0 O O
O 1.06 O 1.09 V
H O H
~N N
N
Ca ~N N~O O O
O -'~ 1.10 Method C
In another variation, peptide coupling of the N-Boc-P2-P3-acid 1.17 with the appropriate P1-P' amide moiety afForded the hydroxyl amide 1.11. Oxidation (Moffatt or Dess-Martin's) resulted in the keto amide 1.12. Deprotection of the N-Boc functionality gave the hydrochloride salt 1.13. Treatment with a suitable isocyanate (or isocyanate equivalent) resulted in the target compound 1.14. ~
V V
H OH H
H ~ON H ~N N.P
~O~N~t~ O ~O ~O~N~N O ~O O
O ~ 1.17 1.11 H O H /~ H O H
~N N.P, ~N N,P, O~N~N O ~O O ---~~ HCLH2N~0 O O
~V
1.12 1.13 V
n N O H
~~~p_NCO" ~N N.P
or ~ Ca ~N N~O'O~ O
equivalent O ~ 1.14 Method D
!n yet another variation, the hydrochloride salt 1.13 was converted to the 4-nitrophenyl carbamate 1.15 by reaction with 4-nitrophenyl chloroformate.
Subsequent treatment with an amine (or amine hydrochloride salt) of choice provided the target compound 1.14.

V
/~ H ~ H H ~ H
~N N.P, ~N N.P, HCLHZN~O TO O ~ O~N~Q O O
O~N ~ i 'I0 1.13 V 1.15 ~ H O H
"cap-NH2" H H ~N N.P, Ca 'N~N~O '0I O
P
O
1.14 Method E
In yet another variation, the dipeptide hydrochloride salt 1.03 was converted to the 4-nitrophenyl carbamate as described above. Treatment with an amine (or amine hydrochloride salt) of choice provided the urea derivative 1.05.
Hydrolysis and further elaboration as described in Methods A/B provided the target compounds 1.14.
V V
.~OCH3 ~ .~OCH3 HCLH~N N~O ~O ~ O~N~O O
1.04 p~N I ~ 'O' ~ 1.16 v n H O H
"cap-NH2" ~OCH3 as above N N N.P, I I -.
H H~ ~ (Method Aj N N~ O O
Cap'N~N~O O Cap' ~ O , O
1.05 ~ 1.14 Preparation of Intermediates:
Preparation of P1,~P' moieties:
Preparation of Intermediates 10.11 and 10.12:
St,_ ep 1:

II HN
N~OC~NS ~ OG2H5 10.01 10.02 A stirred solution of ketimine 10.01 (50 g, 187.1 mmol) under N2 in dry THF (400 mL) was cooled to -78 °C and treated with 1 M solution of K-tBuO
(220 mL, 1.15 equiv.) in THF. The reaction mixture was warmed to 0 °G
and stirred for 1 h and treated with bromomethyl cyclobutane (28 mL, 249 mmol).
The reaction mixture was stirred at room temperature for 48 h and concentrated in vacuo. The residue was dissolved in Et~O (300 mL) and treated with aq. HCI (2 M, 300 mL) The resulting solution was stirred at room temperature for 5 h and extracted with Et20 (1 L). The aqueous layer was made basic to pH --12-14 with NaOH (50 % aq.) and extracted with CH2CI2 (3x300 mL). The combined organic layers were dried (MgS04), filtered, and concentrated to give the pure amine ('10.02, 18 g) as a colorless oil.
Step 2 O O
H2N oC2H5 BocHN pH
10.02 10.03 A solution of the amine 10.02 (18g, 105.2 mmol) at 0 °C in CH2CI2 (350 mL) was treated with di-tart-butyldicarbonafie (23 g, 105.4 mmol) and stirred at rt. for 12 h. After the completion of the reaction (TLC), the reaction mixture was concentrated in vacuo and the residue was dissolved in THF/H20 (200 ml, 1:1 ) and treated with LiOH~H20 (6.5 g, 158.5 mmol) and stirred at room temperature for 3 h. The reaction mixture was concentrated and the basic aqueous layer was extracted with Et20. The aqueous layer was acidified with conc. HCl to pH~1-2 and extracted with CH2CI2. The combined organic layers were dried (MgSO~.), filtered, and concentrated in vacuo to yield 10.03 as a colorless viscous oil which was used for the next step without any further purification.
Step 3 O o BocHN OH BocHN N.OMe i ~Me 10.03 10.04 A solution of the acid 10.03 (15.0 g, 62 mmol) in CH2C12 (250 mL) was treated with BOP reagent (41.1 g, 93 mmol), N-methyl morpholine (27 mL), N,O-dimethyl hydroxylamine hydrochloride (9.07 g, 93 mmol) and stirred overnight at rt. The reaction mixture was diluted with 1 N aq. NCI (250 mL), and the layers were separated and the aqueous layer was extracted with CH2CI2 (3x300 ml). The combined organic layers were dried (MgS04), filtered and concentrated in vacu~ and purified by chromatography (SiO~, EtOAc/Hex 2:3) to yield the amide 10.04 (15.0 g) as a colorless solid.
Step 4 -BocHN N,OMe BocHN H
i ~Me 10.04 . 10.05 A solution of fihe amide 10.04 (15 g, 52.1 mmol) in dry THF (200 mL) was treated dropwise with a solution of LiAIH4 (1 M, 93 mL, 93 mmol) at 0 °C.
The reaction mixture was stirred at room temperature for 1 h and carefully quenched at 0 °C with a solution of KHSO4 (10% aq.) and stirred for 0.5 h.
The reaction mixture was diluted with aq. HCI (1 M, 150 mL) and extracted with CH2Ch (3x200 mL), The combined organic layers were washed with aq.
NCI (1 M), saturated NaHC03, brine, and dried (MgS04). The mixture was filtered and concentrated in vacuo to yield 10.05 as a viscous colorless oil (14 9)~
St__ep 5 O OH
BocHN H BocHN CN
10.05 10.06 A solution of the aldehyde 10.05 (14 g, 61.6 mmol) in CH2CI2 (50 mL), was treated with Et3N (10.73 mL, 74.4 mmol), and acetone cyanohydrin (10.36 g, 127.57 mmol) and stirred at room temperature for 24 hrs. The reaction mixture was concentrated in vacuo and diluted with aq. NCI (1 M, 200 mL) and extracted into CH2CI2 (3x200 mL). The combined organic layer were washed with HBO, brine, dried (MgSO4), filtered, concentrated in vacuo and purified by chromatography (Si02, EtOAclHex 1:4) to yield 10.06 (10.3 g) as a colorless liquid Step 6 OH _ ~ OH
BocHN CN CIH3N OCH3 O
5 10.06 10.07 Methanol saturated with HCI*, prepared by bubbling HCI gas through CH30H (700 ml) at 0 °C, was treated with the cyanohydrin 10.06 and heated to reflux for 24 h. The reaction was concentrated in vacuo to yield 10.07, which was used in the next step without purification.
10 * Alternatively 6M HCI prepared by addition of AcCI to dry methanol can also be used.
Step 7 OH OH
CIH3N OCH3 BocHN OCH3 ~O ~O
10.07 10.08 A solution of the amine hydrochloride 10.07 in CHZCh (200 mL) was 15 treated with Et3N (45,0 mL, 315 mmol) and Boc20 (45.7g, 209 mmol) at -78 °C. The reaction mixture was then stirred at room temperature overnight and diluted with HCI (2 M, 200 mL) and extracted into CH2Cl2, The combined organic layer were dried (MgS04) filtered, concentrated in vacuo and purified by chromatography (EtOAclHex 1:4) to yield hydroxy ester 10.08.
20 Step 8.
OH OH
BocHN OCH3 BocHN OH
n ---~ n O O
a 10.08 10.09 A solution of methyl ester 10.08 (3g, 10.5 mmol ) in THF/H20 (1:1 ) was treated with LiOH~H20 (645 mg, 15.75 mmol) and stirred at rt. for 2 h. The reaction mixture was acidified with aq HCI (1 M, 15 mL) and concentrated in vacuo. The residue was dried in vacuum to afford 10.09 in quantitative yield.
Step 9 OH OH
BocHN OH BocHN NH2 n ----~. n O O
10.09 10.10 A solution of the acid 10.09 (from above) in CH2CI2 (50 mL) and DMF
(25 mL) was treated with NH4CI (2.94 g, 55.5 mmol), EDCI (3.15 g, 16.5 mmol), HOOBt (2.69 g, 16.5 mmol), and NMM (4.4 g, 44 mmol). The reaction mixture was stirred at room temperature for 3 d. The solvents were removed under vacuo and the residue was diluted with aq. NCI (250 mL) and extracted with CHZCh. The combined organic layers were washed with aq. Sat'd.
NaHC03, dried (MgS04) filtered concentrated in vacuo to obtain 10.10, which was used as it was in the following steps. (Alternatively 10.10 can also be obtained directly by the reaction of 10.06 (4.5 g, 17.7 mmol) with aq. H2O2 (10 mL), LiOH~H~0 (820 mg, 20.8 mmol) at 0 °C in 50 mL of CH3OH for 0.5 h.) Step 10 OH _ + OH
BocHN NH2 CIH3N NH2 " ~ O
O
10.10 10.11 A solution of 10.10 obtained in the previous step was dissolved in 4 N
HCI in dioxane and stirred at rt. for 2 h. The reaction mixture was concentrated in vacuo to give the intermediate 10.11 as a solid, which was used without further purification.
St__ ep 11"

OH _ + OH H
BocHN OH CIH3N N
O
O
10.09 10.12 The required intermediate 10.12 was obtained from compound 10.09 using essentially the procedures described above in Steps 9, 10 with appropriate reagents.
Preparation of Intermediate 11.01 Step 1 OH C02tBu 11.02 I I 11.03 To a solution of 4-pentyn-1-ol, 11.02 (4.15g; Aldrich) was added Dess-Martin Periodinane (30.25g; Aldrich) and the resulting mixture was stirred for 45min.
before the addition of (tert-Butoxycarbonylmethylene)triphenylphosphorane (26.75g; ~Aldrich). The resulting dark reaction was stirred overnight, diluted with EtOAc), washed with aq. sodium sulfite. sat. aq. NaHC03, water, brine and dried. The volatiles were removed under reduced pressure and the residue was purified by silica gel column chromatography using 1 % EtOAc in hexanes as eluent to give the desired compound, 11.03 (3.92g). Some impure fractions were also obtained but set aside at this time.
Step 2 C02tBu C02tBu / CBZNH.~ ~OH
11.03 ' ~ 11.04 Using the alkene 11.03 (1.9g) in n-propanol (20m1; Aldrich)), benzyl carbamate (4.95g; Aldrich) in n-propanol (40m1), NaOH (1.29g) in water (79m1), tert-butyl hypochlorite (3.7m1), (DHQ)2PHAL (0.423g; Aldrich)) in n-propanol (37.5m1), and potassium osmate:dehydrate (0.1544g; Aldrich) and the procedure set forth in Angew. Chem. Int. Ed. Engl (1998), 35, (23/24), pp.
2813-7.gave a crude product which was purified by silica gel column chromatography using EtOAc:Hexanes (1:5) to give the desired amino alcohol 11.04 (1.37g, 37°l°) as a white solid.
Step 3 C02tBu C02H
CBZNH, ,OH CBZNH,, ~OH
11.04 11.05 To the ester 11.04 (0.700g) was added 4M HCI in dioxane (20m1; Aldrich) and the resulting mixture was allowed to stand at room temperature overnight. The volatiles were removed under reduced pressure to give the acid 11.05 (0.621 g) as a white solid.
Step 4 OH
CBZHN, .OH CBZNH~N~
''O
11.01 11.05 BOP reagent (3.65g; Sigma) followed by triethylamine (3.45m1) were added to a dichloromethane (20m1) solution of the carboxylic acid 11.05 (2.00g) and allyl amine (0.616m1) at room temperature and the resulting mixture was stirred overnight. The reaction mixture was partitioned between EtOAc and 10% aq. NCI. The organic phase was separated, washed with sat. aq, sodium bicarbonate, water, dried (magnesium sulfate). The crude reaction product was purified by silica gel column chromatography using (EtOAc:Hexanes;
70:30) as eluent to provide the desired amide 11.01 (1.73g) as a viscous yellow oil.
Preparation of Intermediates 12.03 and 12.04 Step 1 O OH
BocHN BocHN OH
'OH
O
U
12.01 12.02 Compound 12.01 was converted to the required material 12.02 using essentially the procedures described for Intermediate 10.11, Steps 3-8.
Step 2 OH OH
BocHN OH HCLH2N NH2 II ~ II
O O
U
12.02 12.03 Compound 12.02 was converted to the required intermediate 12.03 using essentially the procedures described for Intermediate 10.11, Steps 9, 10., Step 3 OH OH H
BocHN OH HCLH2N N
II II
O O
12.02 12.04 Compound 12.02 was converted to the required intermediate 12.03 using essentially the procedures described for Intermediate 10.12, Step 11.
Preparation of Intermediate 13.01 Step 1 OH
02ND ---~ 02N OH
13.02 O
13.03 To a stirred solution of 1-nitrobutane, 13.02 (16.5 g, 0.16 mol) and glyoxylic acid in H20 (28.1 g, 0.305 mol) and MeOH (122 mL) at 0°C-5°C, was added dropwise triethylamine (93 mL, 0.667 mol) over 2 hrs. The solution was warmed to room temperature, stirred overnight and concentrated to dryness to give an oil. The oil was then dissolved in H20 and acidified to pH
=1 with 10% HCI, followed by extraction with EtOAc. The combined organic solution was washed with brine, dried over Na2S04, filtered and concentrated to dryness to give the product 13.03 (28.1 g, 99% yield).
Step 2 OH OH
02N OH , HZN OH
O O
13.03 13.04 5 To a stirred solution of compound 13.03 (240 g, 1.35 mol) in acetic acid (1.25 L) was added 10% Pd/C (37 g). The resulting solution was hydrogenated at 59 psi for 3 hrs and then at 60 psi overnight. The acetic acid was then evaporated and azeotroped 3 times with toluene, then triturated with MeOH and ether. The solution was then filtered and azeotroped twice with 10 toluene to afford 13.04 as an off white solid (131 g, 0.891 mol, 66%).
Step 3 OH OH
H2N OH -r BocHN OH
O O
13.04 13.05 To a stirred solution of the amino acid 13.04 (2.0 g, 13.6 mmol) in dioxane (10 mL) and H20 (5mL) at 0°C, was added 1N NaOH solution (4.3 15 mL, 14.0 mmol). The resulting solution was stirred for 10 minutes, followed by addition of di-t butyldicarbonate (0.110 g, 14.0 mmol) and stirred at 0°C for 15 minutes. The solution was then warmed to room temperature, stirred for 45 minutes and kept at refrigerator overnight and concentrated to dryness to give a crude material. To the solution of this crude material in EtOAc (100 mL) and 20 ice, was added KHS04 (3.36 g) and H20 (32 mL) and stirred for 4-6 minutes.
The organic layer was then separated and the aqueous layer was extracted twice with EtOAc and the combined organic layer was washed with water, brine, dried over Na2S04, filtered and concentrated to dryness to give the product 13.05 as a clear gum (3.0 g, 89% yield).
25 Step 4 OH OH H
BocHN OH HCI.H2N N
O O
13.05 13.01 Compound 13.05 was converted to the required intermediate 13.01 using essentially the procedures described for Intermediate 10,12, Step 11.
Preparation of Intermediate 14.01 Step 1 OH
BocHN OH
02N~'~/~/
O
14.02 14.03 Compound 14.02 was converted to the required material 14.03 using essentially the procedures described for Intermediate 13.01, Steps 1-3.
Step 2 OH OH H
BocHN OH HCLH2N N
..
O O
14.03 14,01 Compound 14.03 was converted to the required intermediate 14.01 using essentially the procedures described for Intermediate 10.12, Step 11.
Preparation of Intermediate 15.01 Step 1 I~CF3 02N~CF3 15.02 15.03 To a suspension of silver nitrite (9 g, 58.5 mmol) in diethyl ether (25 mL) at 0°C was added a solution of 4-iodo-1,1,1-trifluorobutane, 15.02 (10 g, 42.0 mmol) in diethyl ether (25 mL) slowly through an addition funnel (approx. 15 min). The resulting mixture was vigorously stirred at 0°C and warmed to rt.
After 50 h, the solid material was filtered off through a cefite pad. The resulting diethyl ether solution was concentrated in vacuo to give 15.03 as colorless oil, which was used without further purification.

Step 2 OH
02N~CF3 ~ BocHN OH
15.03 O

15.04 Compound 15.03 was converted to the required material 15.04 using r essentially the procedures described for Intermediate 13.01, Steps 1-3.
St_ ep 3 OH OH H
BocHN OH -~. HCLH2N N
O O

15.04 15.01 Compound 15.04 was converted to the required intermediate 15.01 using essentially the procedures described for Intermediate 10.12, Step 11.
Preparation of Intermediate 16.01 O OH H
BocHN OH HCLH2N N

1 p 16.02 16.01 The acid 16.02 (Winkler, D.; Burger, K., Synthesis, 1996, 1419) is processed as described above (preparation of Intermediate 10.12) to give the expected intermediate 16.01.
PREPARATION OF P2 / P3-P~ MOIETIES
Preparation of Intermediate 20.01 H3C~CH3 ~..CO2CHg N
H.HCI
20.01 The amino ester 20.01 was prepared following the method of R. Zhang and J.
S. Madalengoitia (J. Org. Chem. 1999, 64, 330), with the exception that the Boc group was cleaved by the reaction of the Boc-protected amino acid with methanolic HCI (4M HCI in dioxane was also employed for the deprotection).

(Note: In a variation of the reported synthesis, the sulfonium ylide was replaced with the corresponding phosphonium ylide) Preparation of Intermediate 20.04 Step 1 CH3~CN3 O CHsv/CHs BocHN ~OH ~OCH3 + '.~' OCH3 -'~. ' ' ~N
BocHN~ O
H2C~ O O
20.03 20.02 20.01 A solution of commercial amino acid Boc-Chg-OH, 20.02 (Senn chemicals, 6.64 g, 24.1 mmol) and amine hydrochloride 20.01 (4.5 g, 22 mmol) in CH2CI2 (100 mL) at 0 °C was treated with BOP reagent and stirred at rt. for 15 h. The reaction mixture was concentrated in vacuo, then it was diluted with aq. 1 M HCI and extracted into EtOAc (3x200 mL). The combined organic layers were washed with sat'd. NaHC03 (200 mL), dried (MgS04), filtered and concentrated in vacuo, and chromatographed (SiO2, EtOAcIHex 3:7) to obtain 20.03 (6.0 g) as a colorless solid.
Step 2 CH3~CH3 CH3~CH3 ::
'~OCH3 OH
' ~(N
BocHN~O O BocHN~ O
O
20.03 20.04 A solution of methyl ester 20.03 (4.0 g, 9.79 mmol) in THF/H20 (1:1 ) was treated with LiOH~H20 (401 mg, 9.79 mmol) and stirred at rt. for 3 h. The reaction mixture was acidified with aq. NCI and concentrated in vacuo to obtain the required intermediate, free acid 20.04.
Preparation of Intermediate 20.08 Step 1 O
BocHN~OH C~OCH3 OCH3 ' ' ~(N
+ ~~ p N BocHN~O

-~ 20.06 20.05 20.01 A solution of Boc-tert-Leu 20.05 (Flufca, 5.0 g 21.6 mmol) in dry CH~CI2/DMF (50 mL, 1:1 ) was cooled to 0 °G and treated with the amine salt 20.01 (5.3 g, 25.7 mmol), NMM (6.5 g, 64.8 mmol) and BOP reagent (11.6 g, 25.7 mmol). The reaction was stirred at rt. for 24h, diluted with aq. NCI (1 M) and extracted with CH2C12. The combined organic layers were washed with HCI (aq, 1 M), sat'd. NaHC03, brine, dried (MgS04), filtered and concentrated in vacuo and purified by chromatography (SiO2, Acetone/Hexane 1:5) to yield 20.06 as a colorless solid.
Step 2 ~OCH3 - ~OCH3 BocHN~p O ~ HCLH2N~0 O
20.06 , 20.07 A solution of methyl ester 20.06 (4.0 g, 10.46 mmol) was dissolved in 4M HCI in dioxane and stirred at rt. for 3 h. The reaction mixture was concentrated in vacuo to obtain the amine hydrochloride salt, 20.07 which was used without purification.
Step 3 N~OCH3 N~OCH3 HCLH2N~0 O ~ ~ O~N~O O
IIO
O~N
20.07 20.08 A solution of the amine salt 20.07 (840 mg, 2.64 mmol) in THF (14 mL)/acetonitrile (2 mL) was cooled to 0°C. 4-Nitrophenylchloroformate (800 mg, 3.96 mmol) was added followed by pyridine (0.64 mL, 7.92 mmol). The reaction was slowly warmed to room temperature over 3 hrs when TLC
indicated reaction completion. Diethyl ether (50 mL) was added and the resulting precipitate was filtered off. The filtrate was washed with saturated 5 ammonium chloride solution (1 x), brine (1 x), dried (Na2SO4) and concentrated. The residue was purified by flash chromatography using 20/80 EtOAc/hexanes which afforded 1.15 g of the required intermediate 20.08.
Preparation of Intermediate 21.01 St_, ep 1 ~C02H ~' ~C02tBu i i Boc Boc . 21.02 21.03 To a stirred solution of N-Boc-3,4-dehydroproline 21.02 (5.0 g, 23.5 mmol), di-tart-butyl dicarbonate (7.5 g, 34.4 mmol), and 4-N,N-dimethylaminopyridine (0.40 g, 3.33 mmol) in acetonitrile (100 mL) at room temperature was added triethylamine (5.0 mL, 35.6 mmol). The resulting 15 solution was stirred at this temperature for 18 h before it was concentrated in vacuo. The dark brown residue was purified by flash column chromatography eluting with 10-25% EtOAc/hexane to give the product 21.03 as a pale yellow oil (5.29 g, 84%).
St_, ep 2 cy,ci C02tBu CO2tBu Boc , Boc 2~ 21.03 21.04 To a stirred solution of the dehydroproline derivative 21.03 (10.1 g, 37.4 mmol), benzyltriethylammonium chloride (1.60 g, 7.02 mmol) in chloroform (120 mL) at room temperature was added 50% aqueous sodium hydroxide (120 g), After vigorously stirred at this temperature for 24 h, the 25 dark mixture was diluted with CH2CI2 (200 mL) and diethyl ether (600 mL).
After the layers were separated, the aqueous solution was extracted with CH2CI2/Et20 (1:2, 3x600 mL). The organic solution was dried (MgS04) and concentrated. The residue was purified by flash column chromatography using 5-20% EtOAcihexane to afford 9.34 g (71 %) of 21.04 as an off-white solid.
St,. ea 3 c1 ~cl " c1 ~cl ~CF3C02H
~C02tBu ~CO H

Boc H
21.04 21.05 The solution of 21.04 (9.34 g, 26.5 mmol) in CH2CI2 (25 mL) and CF3C02H (50 mL) was stirred at room temperature for 4.5 h before it was concentrated in vacuo to give a brown residue, 21.05 which was used in Step 4 without further purification.
St. ep 4 c1 ~cl c1 ~cl ~ HCI
~CF3C02H \ ~C02Me H
1 ~ 21.05 21.01 Concentrated hydrochloric acid (4.5 mL) was added to a solution of fihe residue 21.05 from Step 3 in methanol (70 mL) and the resulting mixture was warmed to 65°C in an oil bath. After 18 h, the mixture was concentrated in vacuo to give a brown oil 21.01, which was used further without purification.
Preparation of Intermediate 22.01 Step 1 tBoc~ tBoc~
CHO Ph3P~ N w.
---. ~,~ V
THF, reflux 22.02 22.03 Potassium bis(trimethylsilyl)amide (158m1 of a 0.5M solution in toluene;
79mmol) was added to a stirred suspension of cyclopropyltriphenylphosphonium bromide (33.12g; 86.4mmol) in anhydrous tetrahydrofuran (130m1) and the resulting orange mixture was stirred under an atmosphere of nitrogen at room temperature for a period of 1 h., before the addition of the aldehyde 22.02 (9.68g; 42.2mmol) in THF (8m1). The reaction was then refluxed under an atmosphere of nitrogen for a period of 2h. After cooling, methanol, diethyl ether and Rochelles salt were added. The organic phase was separated, washed with brine, dried and concentrated under reduced pressure. The crude reaction product was purified by silica gel column chromatography using EtOAc-hexane (1:99) to EtOAc-hexane (5:95) to provide the allcene 22.03 (8.478) as a yellow oil.
St_ e~ 2 N HtBoc tBoc~ O
N ~~ HN
1.HC1(aq) 2. tBoc-Gly-OSu, Et3N
22.03 22.04 A solution of 1 M HCI in MeOH/MeOAc was prepared by adding 14.2m1 of acetyl chloride dropwise into cold methanol and diluting the resulting solution to 200m1 at room temperature.
The carbamate 22.03 (9.498; 37.5mmol) was dissolved in methanol (12m1) and added to 1 M HCI in MeOH/MeOAc (150m1) while cooled in an ice bath.
The resulting mixture was maintained at this temperature for 1 h., then the ice bath was removed and stirring continued overnight at room temperature. The volatiles were removed under reduced pressure to yield a yellow oil which was used in the next step without purification.
The yellow oil was dissolved in a mixture of THF (30m1) and MeOH (20m1) and treated with triethylamine (15m1; 108mmol) until the solution was pH=9-10. After placing in an ice bath, the mixture was treated with N-Boc-Gly-OSu (11.228; 41 mmol). The ice bath was withdrawn and the reaction stirred at room temp. for 1 h. The volatiles were removed under reduced pressure and the residue was purified by silica gel column chromatography using methanol (1-3%) in dichloromethane providing the desired amide 22.04 (9.098).
St,- ep 3 NHtBoc ~NHtBoc p~ ~O
HN ~ 2,2-dimethoxypropane N
HO O
22.04 22.05 The alcohol 22.04 (9.09g; 33.6mmol) was dissolved in acetone (118.5m1) and treated with 2,2-dimethoxypropane (37.4m1;304mmol) and BFs:Et20 (0.32m1;
2.6mmol) and the resulting mixture was stirred at room temperature for a period of 5.5h The reaction solution was treated with a few drops of triethylamine and the volatiles were removed under reduced pressure. The residue was purified by silica gel column chromatography using 5-25% EtOAc in hexanes to provide the N,O-acetal 22.05 (8.85g).
Step 4 NHtBoc O _..~ O
1. NOBF4 i 2. Pyrrolidine N y 3. Pd(OAe)2 N and N
.~H i~~ .~H
O
O O
22.05 22.06 22.07 The carbamate 22.05 (8.81g; 28.4mmol) was dissolved in acetonitrile (45m1) and the solution was cooled to -4.0°C under an atmosphere of nitrogen.
Pyridine (6.9m1; 85.3mmol) followed by nitrosium tetrafluoroborate (6.63g;
56.8mmol) were added and the resulting reaction mixture maintained below 0°C until TLC indicated that no starting material remained (approx.
2.25h.).
Pyrrolidine (20m1; 240mmol) was added and the cooling bath was withdrawn and stirring was continued at room temperature for 1 h. and then the volatiles were removed under reduced pressure. The residue was quickly passed through a pad of silica gel to provide a yellow oil.
The yellow oil was dissolved in anhydrous benzene (220m1) and palladium acetate (0.317g; 1.41 mmol) was added before heating the resulting mixture to reflux, under an atmosphere of nitrogen for a period of 1.5h. After cooling, the volatiles were removed under reduced pressure and the dark residue was purified by silica gel column chromatography using EtOAc-hexane (1:4) to provide the I) the trans- pyrrofidinone 22.06 (1.94g) followed by ii) the cis-pyrrolidinone 22.07 (1.97g).
Step 5 O -~ O
r N HC1 in MeOAc/MeOH N
~~H
O HO
22.06 22.08 Freshly prepared 1 M HCI in MeOAc/MeOH (10m1; as described above) was added to the N,O-acetal 22,06 and stirred at room temperature for 1 h. The solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography using 0-4%MeOH in dichloromethane as eluent to provide the desired alcohol 22.08 (1.42g), a yellow oil.
St, ep 6 p ~ _-1. LAH
N 2. N-Boc-L-tent-Leu-OH
., H N , HATU BoctHN
HO O HO
22.08 _ 22.09 To a solution of the lactam 22.08 (1.29g; 8.44mmol) in anhydrous tetrahydrofuran (55m1) was added lithium aluminum hydride (2.40g;
63.2mmol) and the resulting mixture was refluxed for 8h. After cooling, water, followed by 15% aq. NaOH were added and the resulting mixture was filtered through celite and the solid was washed thoroughly with THF and MeOH. The solvent was removed under reduced pressure and the residue redissolved in dichloromethane, dried and concentrated under reduced pressure to provide the pyrrolidine, used without purification.
Hunigs base (4.5m1; 25.8mmol) was added to a mixture of N-Boc-L-tart-Leu-OH (1.76g; 7.6mmol), The crude pyrrolidine and HATU (2.89g; 7.6mmol) in anhydrous dichloromethane (50m1) at-60°C, under an atmosphere of nitrogen. The resulting reaction was allowed to come to room temperature slowly, overnight. EtOAc was added and the yellow solution was washed with dil. aq. NCI, sat. aq. sodium bicarbonate, water, brine. The organic layer was dried and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using EtOAc:hexanes (1:3) to give the desired amide 22.09 (2.00g).
Stew 7 ' Jones ;
N N
tBocHN ~~H tBocNN

22.09 22.01 5 The alcohol 22.09 (2.00g; 5.67mmol) was dissolved in acetone (116m1) and cooled in an ice bath for 10min. This solution was then added to a cooled Jones reagent (14.2m1; approx 2mmol/ml) and the resulting mixture was stirred at 5C for 0.5h and the cooling bath was removed. The reaction was stirred for a further 2h. at room temp., before adding to sodium sulfate 10 (23.54g), celite (15g) in EtOAc (100m1). Isopropanol (15m1) was added after 1 min and then stirred for a further 1 Omin, and filtered. The filtrate was concentrated under reduced pressure, providing a brown oil which was dissolved in EtOAc. This solution was washed with water, 3% aq, citric acid, brine, dried and concentrated to provide the desired carboxylic acid 22.01 15 (1.64g) as a white solid.
Preparation of Intermediate 23.01 St_ ep 1 O
N OCH3 ~ , ms 4A°
' H
O~O O
23.02 To the mixture of ester 23.02 (6.0g) and molecular sieve (5.2g) in 20 anhydrous methylene chloride (35 mL) was added pyrrolidine (5.7 mL, 66.36 mmoL). The resulting brown slurry was stirred at room temperature under N2 for 24 h, filtered and washed with anhydrous CH3CN. The combined filtrate was concentrated to yield the desired product, 23.03.
Step 2 Nal, i<ZC03 O
~OCH3 N
O~O O
23.04 mss. vs To a solution of the product 23.03 from proceeding step in CH3CN (35 mL) was added anhydrous IC2C03, methaliyl chloride (2.77g, 30.5 mmoL), Nal (1.07g, 6.7 mmoL). The resulting slurry was stirred at ambient temperature under N2 for 24 h. 50 mL of ice-cold water was added followed by 2N KHS04 solution until pH was 1. EtOAc (100 mL) was added and the mixture was stirred for 0.75h. Combined organic layer was collected and washed with brine, dried over MgS04, and evaporated to yield the desired product, 23.04.
Step 3 O
H3 1 N LiOH / dioxane N~OH
O~O O
--.- . 23.05 The product 23.04 from the preceding step (2.7 g, 8.16 mmoL) was dissolved in dioxane (20 mL) and treated with freshly prepared 1 N LiOH (9 mL). The reaction mixture was stirred at ambient temperature under N2 for 20 h. The reaction mixture was taken in EtOAc and washed with H20. The combined aqueous phase was cooled to 0°C and acidified to pH 1.65 using 1 N HCI. The turbid mixture was extracted with EtOAc (2 x 100 mL).
Combined organic layer was washed with brine, dried over MgS04, and concentrated to give the desired acid, 23.05 (3.40 g).
Step 4 HO,,s NaBH(OAc)3 N~OH
N~OH ~ TIO
O O
O~O O
23.05 23.06 To a suspension ofi NaBH(OAc)3 (3.93g, 18.5 mmoL) in CH2CI2 (55 mL) was added a solution ofi product 23.05 firom preceding step in anhydrous CHZCI2 (20 mL) and acetic acid (2 mL). The slurry was stirred at ambient temperature for 20 h . Ice cold water (100 mL) was added to the slurry and stirred for 1/2 hr. Organic layer was separated, filtered, dried and evaporated to yield the desired product, 23.06.
Step 5 HO,, HO,, ' home N~OH CH2N2 l Et20 l MeOH N
O~O IOI ' ~ O~O O
23.07 23.06 To a solution of the product 23.06 firom preceding step (1.9g) in MeOH
(40 mL) was treated with excess of CH2N2 / Et20 solution and stirred fior overnight. The reaction mixture was concentrated to dryness to yield a crude residue. The residue was chromatographed on silica gel, eluting with a gradient of EtOAc / hexane to afford 1.07 g of the pure desired product, 23.07.
Ste!~6 O
HO,,, OMe OMe N~ BF3 . Me20 / CHZCI2 N
O~O O ~ O~O O
23.08 23.

To a solution of product 23.07 from preceding step (1.36 g) in anhydrous CH2CI2 (40 mL) was treated with BF3. Me20 (0.7 mL). The reaction mixture was stirred at ambient temperature for 20 h and quenched with sat. NaHCO3 (30 mL) ad stirred for 1/2 hr. Organic layer was separated and combined organic layer was washed with brine, dried over MgS04, concentrated fio give crude residue. The residue was chromatographed on silica gel eluting with a gradient of EtOAc / hexane to afford 0.88 g of the desired compound, 23.08.
Step 7 H2 - 10% Pd /C
home -- home 23.01 23.08 To a solution of the product 23.08 (0.92 g) from preceding step in MeOH (30 mL) was added 10 % Pd/C (0.16 g) at room temperature and hydrogenated at ambient temperature under 1 atm. Pressure. The reaction mixture was stirred for 4 h and concentrated to dryness to yield the desired compound, 23.01.

Preparation of Intermediate 50.01 Step 1 50.02 50.03 To a solution of 50.02 (15 g) in MeOH (150 mL) was added cone HCI (3-4 mL) and the mixture was refluxed for 16 h. The reaction mixture was cooled to room temperature and concentrated. The residue was taken in diethyl ether (250 mL) and washed with cold saturated sodium bicarbonate solution, and brine. The organic layer was dried (NaZS04) and concentrated to afford the methyl ester 50.03 (12.98 g) which was carried forward without further purification.
Step 2 50.03 50.04 The methyl ester 50.03 from above was dissolved in methylene chloride (100 mL) and cooled to -78°C, under nitrogen atmosphere. DIBAL (1.0 M
solution in methylene chloride, 200 mL) was added dropwise over 2 h period. The reaction mixture was warmed to room fiemperature over 16 h. The reaction mixture was cooled to 0°C and MeOH (5-8 mL) was added dropwise. A
solution of aqueous 10% sodium potassium tartarate (200 mL) was slowly added with stirring. Diluted with methylene chloride (100 mL) and separated the organic layer (along with some white precipitate). The organic layer was washed with 1 N HCI (250 mL), brine (200 mL), dried (Na2SO4) and concentrated to provide fihe alcohol 50.04 (11.00 g) as a clear oil.
St__ e~ 3 CHO
~OH
50.04 50.05 The alcohol 50.04from above was dissolved in methylene chloride (400 mL) and cooled to 0°C under nitrogen atmosphere. PCC (22.2 g) was added in portions and the reaction mixture was slowly warmed to room temperature over 16 h. The reaction mixture was diluted with diethyl ether (500 mL) and filtered through a pad of celite. The filtrate was concentrated and the residue was taken in diethyl ether (500 mL). This was passed through a pad of silica gel and the filtrate was concentrated to provide the aldehyde 50.05 which was carried forward without further purification.
St__ ep 4 CHO HCLH2N~CO2H
Me 50.05 50.01 The aldehyde 50.05 from above was converted to the desired material 50.01 using essentially the method of Chakraborty et. al (Tetrahedron, 1995, 51 (33), 9179-90).

Preparation of Intermediate 51.01 O O\ /N ~OCH3 H CHs ---,- ~ ~O( CHs 51.02 51.01 The required intermediate 51.01 was obtained from the aldehyde 51.02 using the literature described procedure (T. K. Chakraborty et al., 5 Tetrahedron, 1995, 51 (33), 9179-90).
PREPARATION OF SPECIFIC EXAMPLES
Preparation of Example 1007 U
H O
~N NN2 ~N~O N N~O O O
H
O

Std O
O N~OH O N~O~N
O _ --~ ~ O /~ H
/~
10 1007a 1007b Commercially available compound 1007a (Aldrich Chemical Co., Milwaukee, Wisconsin, USA) was converted to 1007b according to the literature procedure (M. E. Duggan, J. S. Imagire Synthesis 1989, 131-2) in 90% yield. LC-MS: 289 (M+H).
15 St__ ep 2 O N~O~N~ HCI. H2N~O~N~
H --' ~ H
O
1007b 1007c Deprotection of 1007b using 4M HCI in dioxane at room temperature for 3 hrs provided 1007c in quantitative yield. This material was used without further purification.

St. e~3 U
~OCH3 H N
HCI. HZN~O~N~ I ~ O~N~O O
H + 02N~ IIO
1007c ~ 1007d ~OCH3 ~N~O N~N~O O
H ~ O
1007e /
Compound 1007d was obtained from appropriate starting materials/reagents using the previously described procedures (See preparation of Intermediate 20.08).
To a solution of 1007d (200 mg, 0.394 mmol) in dichloromethane (10 mL) at 0°C, under nitrogen atmosphere, was added 1007c (115 mg, 0.512 mmol) followed by DIPEA (0.22 mL, 1.182 mmol). The reaction was maintained at that temperature for 30 min and stored in the freezer (-20°C) for 48 hrs. The reaction mixture was quenched with saturated ammonium chloride solution and the product was extracted into dichloromethane (3 x).
The combine organic layers was washed with brine (1 x), dried (Na2S04), filtered and concentrated. The crude residue was purified by flash chromatography using 30/70 acetone/hexanes which provided the required compound 1007e in 69% yield. LC-MS: 557 (M+H).
Step 4 U
~OCH3 ~N~O N~N~O O
H ~ O
1007e ~OH
~N~O N~N~O O
H ~ O
1007f Hydrolysis of the methyl ester of 1007e to provide the required acid 1007f was carried out as described before (see preparation of Intermediate 20.04, Step 2) with appropriate modifications.
Step 5 v ~OH OH
~N~O N N~O O HCLHzN NHZ
H ~ p + O
10.1 1007f H OH
~N NH2 ~N~O N~N~O O O
H

Coupling reaction of the acid 1007f (0.125 mmol) with the amine salt 10.11 was carried out as described before (see preparation of Intermediate 20.08, Step 1 ) with modifications (HATU instead of BOP, DIPEA instead of NMM; the reaction was carried out at 0°C for 15 min and warmed to 10°C
over 24 hrs) and appropriate amounts of the reagents. The crude material obtained after workup, 10078 was carried forward without purification. LC-MS:
697.2 (M+H).
St._ ep 6 H OH
~N NH2 ~N~O N N~O O O
H ~ O
1007g v H O
~N NH2 ~N~O N N~O O
H
O

To a cold (0°C) solution of the material from above, 1007g (0.125 mmol) in DMSO/toluene (3 mL each) was added EDCI (240 mg, 1.25 mmol) followed by dichloroacetic acid (0.052 mL,,0.625 mmol). After 15 min, the cold bath was removed and the reaction mixture was warmed to room temperature over 16 hr. The reaction mixture was diluted with EtOAc (20 mL) and washed with aqueous 1 N NaHS04 (20 mL). The aqueous layer was separated and extracted with EtOAc (20 mL). The combined organic layers was washed with aqueous 1 N NaHS04 (20 mL), saturated NaHCO3 (20 mL), brine (20 mL), dried (Na~S04), filtered and concentrated in vacuo. The crude residue was purified by flash column chromatography using 40/60 acetone/hexanes to provide the required target compound 1007 (57 mg, 0.082 mmol, 66% yield).
LC-MS: 695.2 (M+H).
Preparation of Example 1044 V
~N~O N N~O O O
H O

St_Jo 1 V
O H H ~OH OH H
~N~O N N N~O ~O HCLH~N N
H ~ p 1044a /-\ ~ 14.01 H OH H
~N N
~N~O N~N~O O
H ~ IIO
1044b Coupling reaction of the acid 1044a, obtained in a similar manner as described for 1007f (see preparation of Example 1007), with the amine salt 14.01 was carried out as described before (see preparation of Example 1007, Step 5). The crude material obtained after workup, 1044b was carried forward without purification. LC-MS: 725.2 (M+H).
St. ep 2:

U
H OH H
~N N
~N~O N N~O O O
H ~ O
1044b ~N~O N~N~O O O
w H ~ 'I0 To a solution of the material from above, 1044b (0.054 mmol) in dichloromethane (5 mL) was added Dess-Martin's periodinane (68 mg, 0.16 mmol). The reaction mixture was stirred at room temperature, under nitrogen 5 atmosphere, for 4.5 hrs. The reaction mixture was diluted with dichloromethane (10 mL) and washed with aqueous 10% Na~S203 (30 mL), saturated NaHC03 (30 mL), brine (30 mL), dried (Na2S04), filtered and concentrated in vacuo. The crude residue was purified by flash column chromatography using 35/65 acetone/hexanes to provide the required target 10 compound 1044 (23 mg, 0.032 mmol, 59% yield). LC-MS: 723.2 (M+H).
Compounds in the following Table 1 and Table 1A were essentially prepared using the above-described procedures (Preparation of Examples 1007 and 1044) with appropriate reagents and modifications as described in the General Schemes for Preparation of Target Compounds, Methods A-E.

Table 1 example Structure Ki* Mol (nM) Weight V
p NHZ
O O
O
1001 ~'~ A 696.885 NH
N"O
~H
O
NHi 1002 O\ 'NH O A 662.868 ~IIN'H
o ~p~O
p NHa 1003 0\ 'NH O A 648.841 "e....... ~IINYH
p O

O
NNi ~O~I,I/O
1004 O\/NH A 682.859 ~m~..,.... ~IN(N

O
~p NNi o O
1005 O\ /NH A 634.815 y,......... NNNN
~q~O
O
NHz O O
1006 O~NH A 668.832 "......... / N
o~

V
F'~ i~-' O
/ ~~ NHz N
1007 O ~ ~ A 694.87 O-\ 'NH
'NH
/J/~~\b V
_ °
NHz N
1008 ° ° ° A 680.843 o"NH
'NH
/~\b //~~ °
'N NHz / NN
1009 ° ° ° A 694.87 O\ 'NH V
'NH
b //~~ °
b NH=
II~IIN
1010 ° ° ° A 708.896 O~NH
'NH
/J/~~\b ~, °
..
1011 ° ° ° A 734.934 o~NH
' o0 /1I\ NH
v _ O
\ /
IO O
1012 ° A 722.923 O\ 'NH
~NH
H
O
\ / ~~ NHi N
O O
1013 ° A 694.87 o\ 'NH
~O
~I~II NH
~N~O
H
V
//~~ O
\ / ~N NHi IIuIIN
O O
1014 ° A 708.896 O\ 'NH
~NH
o.
n O
\ / ~a a~
~O O
1015 ° A 776.895 O NH F
F
F
NH

~b b~

1016 O\ /NH O A 696.885 ~~".",..../ NH
O
N' 'O
H
O
~G G
o II
1017 O\ /NH O A 662.868 ~~."......, ~NH

1018 ~~NH A 676.895 ~"......... NH

NH=
1019 ~~"" A 632.799 J'~~~"..... NH

~b~o Nt+a O O
1020 O~NH A 646.826 ~...,".... /vINH
O
~H~O
r ~
O
'~b b o II
O\ /NH O A 660.852 102 ~1 ...,.,...,(/ NN .
O' ~b~O
O
N
1022 ~ ~ ~ A 720.907 O-\ 'NH
~ ~NHNH
O
V
O
1023 ~ ~ ~ A 708.896 O~NH
\~NyH

_ °
NHa N
O O
1024 ° A 680.843 O\ 'NH V
NHNH
/ '~ O
~t O
NHZ
N
O O
1025 ° A 694.87 O\ 'NH
NHNH
/ 'H O
N
O O
1026 ° A 762.868 O~NH F
O F
F
NH
//~~ O
NHs O II~IIO
1027 O~NH A 646.826 .... NH
p' \O

°
NHa °\ 'NH ° A 660.852 102 ~8 (/NH
O
~H~O
°
NH
/ O II~II°
1029 °~N" A 674.879 """..... NH
°~
~b~°
°
b 1030 ° ° ° A 748.961 o\ 'NH
\IIN~H
V
_ °
1031 ° ° ° A 736.95 °~NH
~NH
O' 1' O
NHz Il 1032 ° ~ A 708.896 O~NH
, OO
'~/\ ' NH
~H~O
O
NHi ~i 1033 ° ° ° A 722.923 o\ 'NH
~NH
°
°
NHZ
N
1034 ° ° ° A 694.87 O\ 'NH
~O
NH
V
~~ O
NHz / IIuIIN
1035 ° ° ° A 680.843 O'\ 'NH
~NH

O
NHz N
1036 ° ° ° A 668.832 O\ 'NH
~NH
O
1037 ° ° ° g 708.896 O-\ 'NH
~O
NH
wl~°
V
°
v o ~a 1038 ° ° ° B 720.907 O\ 'NH
~O
NN
V
O
1039 ° ° ° A 706.881 O\ 'NH
\,IV
NH
a V
_ °
v / ~~. ~~
° °
1040 ° A 694.87 °-\ 'NH
~O
~II NH
\N"O
H
V
~ °
NH=
1041 \ / ° °°II ° A 666.816 °-\ 'NH
~NH
b 'I
°
NHs 1042 ° ° ° A 680.843 O\ 'NH
~NH
°
/ ~b b~
1043 ° ° ° A 708.896 O\ 'NH
~NH I
b V
O
\ / N
1044 ~ ~ ~ q 722.923 O~NH
\~NyH
O
\ /
1045 ~ ~ ~ q 736.95 O\ 'NH
~NH
, a o ' I
V
_ o \ /
1046 ~ ~ ~ p 750.977 q\ 'NH
~NH
O' 1' V
O
\ / ~b b~
1047 ~ I~I ~ q 748.841 O~NH F
O \~y F
F
NH
b _I

°
~a p~
°
1048 ° A 674.879 o~NH
~NH
O
~a a~
1049 ° ° ° A 688.906 o~NH
~NH
a V
°
~a a~
1050 '"' ° °° ° g 686.89 O\ 'NH
~NH
a °~
°
~a a~
II
°~N" A 648.841 1051 ~w,..,....
~NH

\N- 'o O
NHx fl 1052 O~NH A 620.788 "",....../ NH
O
\N~O
//~~ i O
NHx / O IIvIIO
1053 0\ 'NH A 634.815 ~IIH
O' \N"O
V
O
NHx N
O O
1054 ° A 646.826 O\ "NH
~NH
I
/~ O
b NHx ~ ~I,I/N
O O
1055 ° A 660.852 O\ 'NH
~NH

O
° °
1056 ° A 688.906 O\ 'NH
~NH
p w°.
O
p p~
I~° O
1057 ° A 702.933 o\ 'NH
~NH
p O
N p~
N
O O
O
1058 ~,/,..,..,O~NH A 674.879 ~NH
HN- 'o J
;~..
O
~p p~
° II
O
1059 ~'/I,I,I°~"" A 634.815 ~NH

HN- 'O

°
NHz / O IIvIIO
1060 °~"" A 606.761 "".,.... NH
o~
HN~O
O
~~~ NHz O O
1061 °~"" A 620.788 ~,."...... NH
HN"O
V
_ °
b' ~ /
/ N V \O/
O O
O
1062 O\ 'NH B 726.912 y NH
V
_ °
b~°/
° °
1063 O\ 'NH O B 740.938 NH
p °V

_ °
\ /
1064 ° ° ° g 696.885 o\ 'NH
NHNH
/ 'F1 O
\ / N
° °
1065 ° A 720.907 o\ 'NH
~o NH
°
\ /
1066 ° ° ° A 706.881 O~NH
\~NyH
O
\ / ~b b~
°
1067 ° A 696.885 O\ 'NH
~NH

V
/~ °
Jv .p p \ / N~
O O
1068 ° B 724.939 O\ 'NH
~NH
p °
O
\ / ~p ° °
1069 ° B 754.965 o\ 'NH
~NH
p °
V
° ~
p p' //
\ //
O O
1070 ° A 734.934 O\ 'NH
~NH
p :....,.<.
_ °
\ / ~b p~
N
o O
1071 ° A 710.912 o\ 'NH
NHNH
J 'p V
O
\ / N
O O
1072 ° A 710.912 O\ 'NH
NHNH
Fi O
\ /
1073 ~ ~ ~ p 718.892 O\ 'NH
~NH
V
O
\ / ~x b~
IIN
O O
1074 ° B 724.939 o\ 'NH
~NH
I
:' O
~G G
o II
O
1075 ~,r,IL.O~NH p 648.841 NH
HN O
J

°
NHa O O
1076 ° I NH A 634.815 ~,~........ NH
°~
HN"o J
3 ~~:.
O
NHa ° O
1077 °~NH A 620.788 NH
HN"°
J
_ °
1078 ° ° ° B 694.87 °\ 'NH
\I,NYH
b °~

O
~b IIN
1079 ° ° ° A 720.907 °-\ 'NH
° NHNH

O
NHz N
O O
1080 ° A 668.832 O\ 'NH
\,INVH
O
NHi N
O O
1081 ° A 660.852 o.\ 'NH
~NH
H
~~ O
~N NHi \ / IIuIIN
O O
1082 ° A 646.826 o-\ 'NH
~NH
~i V
O
~G
~O O
1083 ° A 728.851 O~NH F
O \~Y F
F
NH

V
O
~b O O
1084 ° A 686.89 O\ 'NH
NHNH
O
j~b b~
~O O
1085 ° A 688.906 O\ 'NH
~NH

N
O O
1086 ° A 684.874 O\ 'NH
O NHNH
/~ O
J"N NHr ~ I~IN
O O
1087 ° A 674.871 O\ 'NH
~NH
H

O
NHa N
O O
1088 ° A 660.844 O-\ 'NH
~NH
H
O
b~
1089 ° ° ° A 702.924 O~NH
\~NVH
V
:' k /~ O
~N
~N~
1090 ° ° ° A 698.892 o_\ 'NH
° ~NH
O
H
N
N O
1091 ° A 686.882 o\ 'NH .
NHNH
O

°
~G
1092 ' ' ° °° ° A 688.898 O'\ 'NH
NH
/ \ O
//~\ H
.N N' ~
~ ~ I~I V \N
1093 ° ° ° A 700.908 °'\ 'NH
~~~° ~NH
V
°
~N aV
° °
1094 ° A 688.898 °~NH
~NH
V
:., °
~b b~
1095 ° ° ° A 712.919 O'\ 'NH
\IIN~H

°
~b 1096 ° ° ° A .716.951 °\ 'NH
~NH
°
~b b~
1097 ° ° ° A 702.924 °\ 'NH
NH
V
°
N
lOgg ° ° ° A 714.935 °~NH II
NH
V
°
~b b~
° °
1099 °~NH ° A 714.935 ~IINyH

O
~a a~
O
1100 0\ 'NH O A 700.908 NH
a O
U
O
~a a~
O O
1101 O\ 'NH O A 710.903 NH
a °
Table 1 A
Example Structure K~* LC-MS
# ~nM) CM+H) ~a NH
IIuOII O
1102 O\ 'NH ° A 729.2 a NH

~N NH
II~IIN
O O
O
1103 O\ 'NH B 715.2 NH

NH
N
O O
O
1104 °~NH ~ I A 725.2 NH
p O
NH
N
O O
O
1105 0\ 'NH II A 727.2 NH
p O
NH
N
O O
1106 ° A 731.2 O\ 'NH
~O
~II NH
HN"O

°
NH
N
° O
1107 ° A 717.2 O\ 'NH
\IIvO
~IIII NH
HN"o NH
N
O O
1108 ° A 727.2 O\ 'NH
~O
~II NH
HN"O
O
NH
N
O O
1109 ° A 729.2 D-\ 'NH
~O
/I'I~ NH
HN"O
'b NH
Iluo 0 v o 1110 O\ 'NH B 772.2 °
~II NH
HN"o °
NH
O O
O
1111 O\ 'NH B 757.2 °
IIII NH
HN~O
NH
N
O O
O
1112 o\ 'NH II A 767.2 y°
NH
HN V' ~ O
~N NH
~ ~ ~I,I/N
O O
O
1113 O\ 'NH Il B 769.4 y°
~II NH
HN"
NH
\ / IIuIIN
O O
1114 ° A 715.2 o\ 'NH
~0 ~II NH
HN"O

O
NH
N
1115 . '~° ° ° A 724.939 O~NH
\1Y0 ~II NH
HN"O
~~ O
NH
\ / IIuIIN
O O
1116 ° A 729.2 O\ 'NH
~0 ~II NH
HN"O
O
NH
N
O O
1117 ° A 727.2 O~NH II
O
/I'I~ NH
HN"O
~~--''~~ O
NH
\ / IIuIIN
O O
1118 ° A 711.2 ~N"
NH

°
NH
N
O O
1119 ° B 701.2 O\ 'NH
NHNH
/ ' NH
N
O O
1120 ° A 741.2 O\ 'NH
~O
/I'I~ NH
HN"
O
NH
N
O O
1121 ° A 741.4 O~NH
t \~vO
/I'I~ NH
HN"O
Ki* range: A = <75 nM, B = 75-250 nM; C = > 250 nM
Preparafiion of Example 1441:
H O
O N~N NH2 ~//NH~ O O

Ste~~ 1 H02C NHBOc HOH2C NHBoc 1441a 1441b To a ice cooled solution of 1441a (4.28 g, 10.08 mmol) in anhydrous ether (100 mL) was added LAH (1.53 g, 40.32 mmol) and the reaction mixture was allowed to warm to room fiemperature overnight. The reaction mixture was cooled to 0°C and EtOAc (3 mL) was added to it, followed by aqueous KHS04 (10 g in 25 mL of H20). The gummy residue was extracted with ether (300 mL) and the organic layer was washed with satd. NaHC03, followed by 10% aq. KH~P04, brine, dried over MgS04, filtered and concentrated. The crude residue was purified by flash chromatography over Si02 using ethyl acetate/DCM (1:4) to yield 1441 b (2.14g, 92%).
Ste~2 HOH2C NHBoc w0~0 NHBoc 1441b 1441c To a ice cooled solution of 1441 b (743 mg, 3.24 mmol) in anhydrous pyridine (10 mL) was added methyl chloroformate (1 mL, 13 mmol), followed by DMAP (1.6 g, 13 mmol) and the reaction mixture was allowed to warm fio room temperature over 2 days. The reaction mixture was concentrated and EtOAc (100 mL) was added to it followed by 100 mL of ice-cold (5%
KH2P04containing 0.05 volumes of 1 M H3P04). The organic layer was washed with brine and dried over MgS04, filtered and concentrated. The crude was purified by flash chromatography over SiO2 using ethyl acetate/DCM (1:4) to yield 1441c (931 mg, 100% yield).
Ste ~a 3 ~O~O NHBoc y~0 NCO
1441c 1441d 1441c was dissolved in 4M HCI in dioxane (10 mL) and concentrated after 30 min. Saturated NaHC03 (25 mL) was added to an ice-cold solution of the crude hydrochloride salt (194 mg, 1 mmol) in CH2CI2 (25 mL). The reaction mixture was stirred vigorously for 10 min and COCI2 (1.85 M solution in PhMe, 4 mL) was added to it and stirring was continued at room temperature for 1 h. The organic layer was separated, dried over MgS04, filtered and concentrated to half the volume to yield 1441d as a 0.05 M
solution in CH2CI2.
Ste ~a 4 ..
' ' OH
/~'~ OH
O N OH HCI.H2N NH2 O ~N NH2 BocNH-J O ~ O -~ BocHN~ j0 O
1 ~ 1.17 12.03 1441a To a -20°C solution 1.17 (10.4 g, 28 mmol; obtained by the hydrolysis of 20.06 using the procedure described for Intermediate 20.04, Step 2) in DCM (300 mL) was added HATU (1.05 equiv, 29.4mmol, 11.2g), amine salt, Intermediate 12.03 (1.0 equiv, 28 mmol, 5.48 g). After 10 min at -20°C, DIPEA
(3.6 equiv, 100 mmol, 17.4 mL) was added. Reaction was stirred at this temp for 16 hr. After 16 hr, the reaction was diluted with EtOAc and washed successively with NaHC03, citric acid (10% w/w) and brine. Organic layer was dried over MgS04, filtered and concentrated in vacuo to yield 14 g of the required intermediate 1441e.
Step 5 ... , ...
O N~ N OH NH2 O ~N O NH2 BocHN-' O ~ -' BocHN~- ' ~O O
1441e 1441f The hydroxyamide 1441 a was oxidized to the required ketoamide 1441f in a manner described for Example 1007, Step 6. LC-MS = 507 (M+H)+
Step 6 C N N C NH2 O N' N O NH2 BocHNJ C 0 ~ HCLH2N-' O O
1441f 14418 Deprotection of the t-Boc functionality of 1441f to give the required material 1441 g was carried out as described for Example 1007, Step 2.
Step 7 ,~
~O~O NCO O
'N NHS
NH2.NCI~ O O
1441d O
N NHz O

To a cooled solution (O °C) of the amine hydrochloride 1441 g (20 mg, 0.045 mmol) in CH2CI2 (2.0 mL) was added 1441d (1.35 mL, 0.135 mmol), followed by DIPEA (63 p,L, 0.4 mmol). The reaction mixture was stirred at room temperature for 1.2 h, diluted with ethyl acetate (20 mL), washed with 3% citric acid, brine, dried over MgSO~., filtered , concentrated and purified over Si02 using EtOAcIDCM (1:9 to 9:1 ) to yield 1441 (23 mg). LCMS = 620.3 (M+H)+.
Compounds in the following table (Table 2) were essentially prepared using the above described procedures (Preparation of Example 1441 ) with appropriate reagents and modifications as described in the General Schemes for Preparation of Target Compounds, Methods A-E.

Table 2 Example Ki* Mol Structure (nM) Weight O
NHz O O
O
1401 O I NH A 669.817 J",........ NN
~O
I, O
N~
O O
O
1402 O~NH ,4 683.843 YINH
o O"O
O
Il b b~
° II
°
1403 O\/NH g 697.87 ~~~........[/~IN(H
O
I~

O
NHz O O
1404 O~NH A 649.826 JH........./ NH
O
~o~O
// O
NHa O O
1405 O\ /NH A 663.853 "",..... ~NH
~O~O
O
O\ /NH O g 677.88 140 ~6 y",~...... NH
--y 'O o O
NHi O O
1407 O\ /NH A 633.784 ~;IINH
~O~o O
Ntia O O O
1408 °~"" A 647.81 /NN
O' ~~O
V O
O
1409 °~"" B 661.837 ",.,...... NH
O
O
NHa O O O
1410 °~"" A 635.799 N"
O' \O
/~f NHa I~OI O
O
1411 O\ 'NH A 649.826 ~~..... III;""
o/ 'O

p N
N
p NH p A 663.853 .,.....
p p p NHi 1413 p~NH p , A 593.719 ......./ NH
p~
\p~ 'O
O
p NH, 1414 p~NH A 621.773 ~.....,..... NH
~p~0 O
NHi / O IIvIIp 1415 O~NH A 647.81 /NH
pI/
~~p O
b \N/
1416 O NH ° A 621.773 °J~
~O~O
°
a~
1417 °~NH A 649.826 ....../ NH
o~
~O~O
O
~a ° II
1418 °~"" ° A 675.864 ,.,.,...... NH
~O
~~''~~''''~~ O
y~ NHi / O IIvIIO
1419 O\ /NH A 607.746 ~'~.",... ~NH
b"O

O
NHz O O
1420 O\ /NH A 621.773 ",.,....( /NHNH
O' ~O~O
O
NH
O O
1421 O~NH A 635.799 ~.~"~.....( /NH
O' \O~O
O
~b b~
° II
1422 ~~° C 689.891 O\ /NH
~O
~ ~ ~II NH
'O"O
st O
Il b b~
° II
1423 ~~° B 647.81 O\ 'NH
~NH
O

//~~ O
~p NHz / ° OOII O
1424 O"NH A 607.746 ~.",....... ~NH
\0"O
O
NHi O O
1425 O~NH A 635.799 ",...,... NH
o~
~O~o NHZ
O O
1426 O\ /NH A 661.837 7~n"..... ~NH
~~O
O
NHi N
1427 ~~° ° ° A 661.837 O\ /NH
~O
\~~II NH
Y 'O"O

°
NHi 1428 '~° A 619.757 Q\ 'NH
~NH

NHz N O
1429 '~° A 675.864 O\ /NH
~O
~ ~ /1\I NH
Y 'O- 'O
I O
NH=
N O
1430 '~° A 633.784 O\ 'NH
~0 ~II NH
\0"O
U
//~~ O
NHs \N/ IIuIIO
1431 '~° B 709.881 O\ /NH
Q ~NH
O_ 'O

O
NHi O O
1432 0y /NH A 645.795 ~NH
O' ~O~O
\Vj O
NHy O O O
1433 °~N" A 659.821 NH
~O~O
\V/ O
'N
'N/
O O
1434 O\ /NH O B 673.848 D,."~,.' NHNH
O' ~~O
/~ O
y~ NHz ~N~ I~IO
1435 '~° B 695.854 o\ /NH
~IN'H

°
NHa O °
1436 poNH A 605.73 o"..,.. NH
\O °
O
NHi O O
1437 OoNH A 619.757 o........ INN
°I~
\o"O
O
1438 OoNH O B 633.784 o....... NH
\O"O
O
G b 'N/ ~O D o 1439 '~o° ~ B 723.908 poNH
°
NH
y O
~p p \N/
O
1440 °~"" B 647.81 ""...... NH
O' 'O

~p NHz O O O
1441 °~"" A 619.757 ~,......... /NH
O
O" O
~~ O
~p NHz II~IIO
1442 °~"" A 633.784 "'e,... NH
~O
J::::
Il p O p~
° II
O
1443 O~NH g 675.864 INH
O

/~ 0 C. 1 .N NHz . 1l o a 1444 O~NH p 647.81 ~,~~.,......(/ NH
O
O"O

NHi O O
O
1445 ~~NH p 661.837 ~~,..,..".. NH
O"O
O
II I

O NH
1446 ~ B 687.875 -.M......

NHi O O
O NH
1447 ~ A 659.821 "........

O
~~a NHx O O

O
O NH A
448 ~ 73.848 ."...

....

Ki~ range A = <75 nM; B = 75-250 nM; C = >250 nM
Preparation of Example 1655 U
w N N~ O O
O ~ O
O

Step 1 H H
~O~N~OH ~ ~O~N~OCH3 O~ -I O
1655a 1655b To a solution of commercially available compound 1655a (Aldrich Chemical Co., Milwaukee, Wisconsin, USA, 950 mg, 4.38 mmol) in acetonitrile (40 mL) at room temperature was added methyl iodide (4.63 mL, 74.42 mmol). Silver (I) oxide (1.62 g, 7.01 mmol) was then added under nitrogen atmosphere and the reaction mixture was refluxed for approximately 16 hrs. (Note: The reaction flask was covered with aluminum foil). At this time, the reaction mixture was cooled to room temperature and filtered through a pad of celite. The filter cake was rinsed with ethyl acetate several times.
The combined filtrate was concentrated and purified by flash column chromatography using 20/80 to 40!60 ethyl acetate/hexanes to afford 720 mg of the expected product, 1655b.

Step 2 H
~O~N~CCH HCI. H2N~CCH

O
1655b 1655c Conversion of 1655b to compound 1655c proceeded in quantitative yield using previously described procedure (Step 2, Example 1007).
Step 3 HCI. H~N~OCH3 O.C~N~OCH3 1655c 1655d To a solution of compound 1655c (514 mg, 3.08 mmol) in dichloromethane (20 mL) was added saturated sodium bicarbonate solution (20 mL). This mixture was stirred vigorously and cooled to 0°C.
Phosgene (20 wt% in toluene, 6.5 mL) was added dropwise. The reaction mixture was stirred vigorously for 4.5 hrs while maintaining the temperature at or below 5°C. At this time the reaction mixture was poured into a separatory funnel and the organic layer was separated. The organic layer was washed with saturated ammonium chloride solution (1 x), water (1 x), dried (Na2S04) and concentrated. The residue, 1655d, was diluted with dichloromethane (10 mL) and used further as a 0.308M solution.
Step 4 V
OoC~N~OCH3 * N
HCl.H2N~0 O
1655d O 1655e U
~O~
N
--; ~O N~N~O O
V \O
1655f To a cold (0°C) solution of 1655e (176 mg, 0.5 mmol; 1655e was prepared as described for Intermediate 20.08, Steps 1 and 2 using appropriate starting materials) in dichloromethane (4 mL) was added 1655d (0.308 M solution, 4.87 mL, 1.5 mmol) followed by DIPEA (0.276 mL, 1.5 mmol). The reaction mixture was maintained at 10°C for 16 hrs. The reaction was quenched with saturated ammonium chloride solution and the aqueous layer was extracted with dichloromethane (3 x). The combined organic layer was washed with brine, dried (Na2S04), filtered and concentrated in vacuo.
The crude residue was purified by flash column chromatography using 20/80 acetone/hexanes to provide the required compound 1655f (240 mg, 100%
yield). LC-MS: 480.1 (M+H).
Step 5 V
N
w0 N~N~O O
O
H O
1655f ~N NHS
- ~'N
O N~N~O 0 O
IIO

Compound 1655f from above was converted to the required target compound 1655 using the intermediate 10.11 and procedures described above (Steps 4 - 6, Example 1007). LC-MS of 1655 = 618.1 (M+H).
Preparation of Example 1614 V
H O
~N NH2 N N~ O O
O ~ O
O

St_ e~1 BocHN~OH BOCHN~O \
1655a 1614a To a stirred solution of N-Boc-tert-leucinol 1655a (2.0 g, 9.22 mmol), phenol (1.0 g, 10.6 mmol) and ADDP (3.8 g, 15.1 mmol) in CH2C12 (80 mL) at rt was bubbled argon gas for 15 min. Triphenylphosphine was then added in one portion. The resulting solution was stirred at RT for 18 h. The precipitates were filtered off and washed with diethyl ether (2 X 30 mL). The filtrate was concentrated in vacuo. The residue was purified by flash column chromatography eluting with 2-10% EtOAc/hexane to give the desired product 1614a (0.33 g, 12%).
Step 2 BocHN~ \ I ~ HCLH2N~0 \
O
1614a 1614b Compound 1614a (0.32 g, 1.13 mmol) was dissolved in a 4 M
hydrogen chloride solution in p-dioxane (20 mL) and stirred at RT for 3 h. It was concentrated in vacuo to give compound 1614b, which was used without furfiher purification.
Step 3 HCLH~N~ \ I ~ O=C=NCO \ I
O
1614b 1614c Compound 1614c was prepared from 1614b according to the procedures described for Example 1655, Step 3.
Step 4 U
o / N NHS
O=C=N \ I / H H
I
O
N N~O O O
O
O
1614c ~ 1614 The isocyanate 1614c was converted to the target compound 1614 as described in the General Schemes, Method C using the appropriate reagents and Intermediates.
Preparation of Example 1610 U
H O
~N NH2 N
N N ~O O O
O

Step 1 CbzH N NCH CbzH N ~C~
1610a ' 1610b To a stirred suspension of anhydrous magnesium sulfate in anhydrous CH2C12 (40 mL) at RT was added concentrated sulfuric acid (0.32 mL, 5.76 mmol). The mixture was vigorously stirred for 30 min before a solution of 1610a (2.0 g, 7.90 mmol) in anhydrous CH2CI2 (15 mL) was added. The mixture was then vigorously stirred at RT for 68 h. Saturated NaHC03 solution (50 mL) was added cautiously, along with CH2CI2 (100 mL) and water (50 mL). Two phases were separated, and the aqueous layer was extracted with CH2CI2 (2 X 100 mL). The combined organic solution was dried (MgS04), filtered and concentrated in vacuo to give 1610b.
Step 2 CbzH N ~Ok ~ H2N ~Ck 1610b 1610c A suspension of compound 1610b and 10% Pd-C in absolute ethanol was vigorously stirred under a hydrogen atmosphere for 4 h. The catalyst was filtered off through a celite pad. The filtrate was concentrated in vacuo to afford 1610c which was used without further purification.
Step 3 H~N~ ~ O=C-NCO
O
1610c 1610d Compound 1610d was prepared from 1610c according to the procedures described for Example 1655, Step 3.
Step 4 U
/~ H O
~N NH2 O=C=N~ N
- O~ -- ~O N N ~O O O
O

1610d The isocyanate 1610d was converted to the target compound 1610 as described in the General Schemes, Method C using the appropriate reagents and Intermediates.
Preparation of Example 1620 U
H O
~N NH2 N
O N N~~ O O
O

St, e~p 1 BocHN~OH BocHN~O
1655a 1620a A suspension of the alcohol 1655a (3.46 g, 12.8 mmol), benzyl bromide (10 mL, 84.2 mmol) and silver (I) oxide (5.0 g, 21.6 mmol) in acetonitrile was stirred vigorously at 76 °C in an oil bath overnight (18 h), The solid material was filtered off and the solution was concentrated in vacuo. The product was purified by flash column chromatography eluting with 5-40% EtOAclhexane to give the desired product 1620a (0.78 g, 20%).
St_ep2 BocHN~ ~ HCLH2N~0 O
1620a 1620b Compound 16120b was prepared from 1620a according to the procedures described for Example 1614, Step 2.
Step 3 HCLHZN~O I ~ O=C=NCO
1620b 1620c Compound 1620c was prepared from 1620b according to the procedures described for Example 1655, Step 3.
Ste p 4 U
/~ H O
/ ~N NH2 _ _ ii O C Nip ~ O N~N~O O O
IOI
1620c 1620 The isocyanate 1620c was converted to the target compound 1620 as described in the General Schemes, Method C using the appropriate reagents and Intermediates.
Preparation of Example 1629 U
H O
~~N NH2 N ~( O O
O
O~NH
NH
Bn0'~~

Step 1 n OH
O ~N NH2 ~ p NH2 BocHN-! O O HCI.H2N
1441e 1629a To 1441e (600 mg) was added 4M HCI in dioxane (25 mL). The reaction was stirred at room temperature for 30 min. and concentrated to yield a white solid, 1629a (490 mg), which was carried forward without purification.
Step 2 U
H OH
~N NH2 Bn0 NCO + N O O
'O
1629b HCLH2N
1629a U
H O
~~N NH2 N
O O
O
O~NH
NH
BnO

To a cooled (0 °C) solution of compound 1629a (395 mg) in CH2C12 (25 mL) was added Et3N (0.57 mL), followed by the isocyanate 1629b (Robinson, Ralph P.; MarFat, Anthony. Eur. Pat. Appl. (1991 ), EP 436333 A2 19910710, 53 pp) in a manner described above (Example 1655, Step 4). The crude hydroxyamide obtained was used without purification.
A solution of the crude hydroxyamide in toluene-DMSO (2.0 mL each) was cooled to 0 °C. To the reaction mixture was added EDCI.HCI (410.0 mg), followed by dichloroacetic acetic (0.087 mL), after stirring for 2h at room temperature, it was diluted with EtOAc, washed with 1 N HCI, satd. NaHC03, brine, dried over MgS04, filtered, concentrated to yield a white solid which was purified by chromatography over silica gel using acetone-hexane (40:60) to afford the title compound 1629 (280.0 mg) as a white solid: Mass spectrum for C33H49N5O6 (611.77); found FAB (M+H)+ = 612.5 Preparation of Example 1628 V V
H O : : H O
N~N NH2 N~N NH2 O O ~ tOI O
O O
O~NH O~NH
NH NH
BnO~~~ 1629 HO~~~ 1628 To a solution of compound 1629 (37.0 mg) in MeOH (2.0 mL) was added Pd-C (10 % w/v, 5.0 mg) and the reaction was stirred under hydrogen atmosphere for 1 h, filtered through a pad of celite, concentrated and purified by chromatography over silica gel using acetone-hexane (4:6) to yield the required compound 1628 (22.Omg) as a white solid. Mass spectrum for C26H43N5O6 (521.65); found FAB (M+H)+ = 522.6.
Preparation of Example 1633 V
OH
~NH NHz N
Bn ~ CO + O
~i~0 HCLHZN
1629b 1633a V

~NH NHz O O
O
O~NH
BnO~NH
\ 1633 The required title compound 1633 was obtained from the isocyanate 1629b and compound 1633a (prepared from 1.17 and 10.11 ) using procedures described for Example 1629. Mass spectrum for C34H51 N5O6 (625.80); found FAB (M+H)+ = 626.8.
Preparation of Example 1632 V V

N~NH NH2 N~NH NH2 O O O O
O ' O
O~NH O~NH
NH NH
BnO~~~ 1633 HO~~~ 1632 To a solution of compound 1633 (10.0 mg) in MeOH (2.0 mL) was added Pd-C ( 10 % w/v, 2.0 mg) and the reaction was stirred under hydrogen atmosphere for 1 h, filtered through a pad of celite, concentrated and purified by chromatography over silica gel using acetone-hexane (4:6) to yield the title compound 1632 as a white solid (4.2 mg). Mass spectrum for C27H45N5O6 (535.68); found FAB (M+H)+ = 536.7.
Preparation of Example 1647 V
~NH v NH2 N
O O
O
O~NH
NH

Ph Ph-Step 1 O~O~Ph OH
Ph' X C02H Ph C02Me 1647a 1647b To a stirred solution of the commercially available compound 1647a (Aldrich Chemical Co., Milwaukee, Wisconsin, USA, 250.0 mg) in MeOH was added trimethylsilyl diazomethane (2.0 mL, 2M solution in PhMe). After 20 min the solvent was removed and the crude was redissolved in CH2CI2 (2.0 mL) and Benzyloxymethyl chloride (1.5 equivalent) was added along with Et3N
(1.5 equivalent). The reaction mixture was stirred overnight, diluted with EtOAc, washed successively with 5 % Na2S203, satd. NaHCO3, 1 N HCI, brine, dried over MgS04, filtered, concentrated to yield a white solid which was purified by chromatography over silica gel using EtOAc-hexane (1:3) to afford the compound 1647b (413 mg) as a white solid: Mass spectrum for C20H2404 (328.40); found FAB (M+H)+ = 329.4.
Step 2 O~O~Ph Of~O~ph O~O~ph Ph C02Me ---~ Ph C02H ~ ph NCO
1647b 1647c 1647d To a solution of 0.413 g of compound 1647b in MeOH/H20 (5.0/0.5 mL) was added 0.735 g of KOH. The reaction mixture was refluxed overnight, cooled to room temperature and concentrated. The crude was redissolved in H20 (10.0 mL) and acidified with 10 % aqueous HCI and extracted with CH2Ch, dried over MgS04, filtered and concentrated to afford the corresponding carboxylic acid 1647c (392 mg). The crude was directly used in the next step. To a solution of 123.2 mg of acid 1647c in toluene (5.0 mL) was added DPPA (0.09 mL) and Et3N (0.055 mL). The reaction mixture was heated at 110 ° C for 40 min, cooled and washed with satd. NaHC03, dried over MgS04, filtered and concentrated to afford the isocyanate 1647d. The crude obtained was used without purification.
Step 3 V
OH
O~O Ph '~NH NHS
Ph NCO + -~ O O
O
NH2.HC1 1647d 1629a U
O
~NH NHS
-~ O O
O
O~NH
NH

O-/ Ph 2~ Phi The isocyanate 1647d was treated with compound 1629a (90.0 mg) in a manner described in Example 1629 to provide the title compound 1647.
Mass spectrum for C40H55N5O7 (717.89); found FAB (M+H)+ = 718.8.
Preparation of Example 1648 U

~NH NH2 O
N
O O ~~NH NH2 IIN
O NH O O
'O
~H O N H
NH

HO
Ph To a solution of compound 1647 in MeOH was added 6N HCI after 30 min, the MeOH was removed and the crude was redissolved in ethyl acetate and washed with satd. NaHC03. The crude was purified by chromatography over silica gel using acetone-hexane (40:60) to afford the title compound 1648 (25.0 mg) as a white solid: Mass spectrum for C32H47N5O6 (597.75); found FAB (M+H)+ = 598.7.
Compounds in the following table (Table 3) were essentially prepared using the above described procedures (Preparation of Examples 1610, 1614, 1620, 1628, 1629, 1632, 1633, 1647, 1648, 1655) with appropriate reagents and modifications as described in the General Schemes for Preparation of Target Compounds, Methods A-E.

Table 3 Example i'~1* MOi Structure (nM) Weight °
NH=
" ° fl 1601 '~° B 577.763 o~NH
~0 NH
O
NHz N
1602 ° ° ° g 563.736 o\ 'NH
~0 NH
V
°
b NHi 1603 ~"H A 637.818 ~NH

NHi 1604 \ / ° A 547.693 o~NH
~NH
(V~(H~o O
NHi 1605 ° A 665.871 o\ 'NH
I ~ ~NH
/~ O
'N NHT
/ IIvIIO
1606 ° A 651.845 o' 'NH
I ~ ~NH
V

NHi IIIIo 1607 '' Y \° A 561.72 O\ 'NH
~NH
//\~.///~H~o O
NHs 1608 ~ ~ ~ g 679.855 o~NH
\~yO
~ ~NH
O
/~\%
//~~ O
~b NHi II~IIN
O O
1609 ° B 691.866 O~NH V
\~yO
NH
//~~ O
NHz / 0 0o1 O
1610 O\ 'NH A 619.843 ~NH
o/
O
NHi O
1611 ~~NH A 633.827 .""..... NH
~O

°
NHi 1612 O"NH O A 647.854 ~.."......(/~IINyH
O' /I 'O
O
~N NHz ~ ~ ~N
1614 '~° ° ° B 625.807 O\ 'NH
""..... NHNH
O
NHi °
1616 '~° C 663.856 O\ 'NH
'NH
O
NHi N
1617 ° ° ° B 573.731 o\ /NH
~NH
~OH

°
NHz N o 1618 ~~° B 639.834 O~NH
---ye""" /\1IN~H
O' ~b NHs °
1619 ~./...., o~NH g 653.86 ~NH
//~~ O
b NHi II~IIO
O
1620 ~"",., ° '[ NH B 639.834 ~NH

9'E
//~~''~~ O
'N NHz \ / IIuIIN
1621 ~~° ° ° A 665.871 O~NH
o \~NYH

V
°
~b NH, ° o 1622 ° C 725.926 O~NH
\~~N/H
V
°
NHs N
1623 ° ° ° B 691.909 O~NH
~NH
~~ O
NHi ' / II~IIN
1624 ° ° ° A 601.785 o\ 'NH
~NH
/~~(\IOH
V
/~ O
J, N NHS
~ ~ ~N
1625 ° ° ° B 635.802 ~NH
~NH
OH

°
~p NH, \/ ~N
1626 , ° A 575.747 °~NH
\~~N/H
H°
I~~,,1 O
p NHi '' 'IIII~O
1627 O\ 'NH ° A 591.79 ~~~.~,.,... ~INyH
'~1 O
~~p NHr ' / II~IIN
1628 ~~° ° ~ A 521.656 °~NH
~NN
Ho~
rr!!--~~~' 0 ~~p NHi 'N/ IIuII°
1629 ° B 611.78 O\ 'NH
~NH

°
NHz N
° O
1630 ° A 623.791 o\ 'NH v ~NH
O
NHs N
O °
1631 ° A 637.818 °\ 'NH
NHNH
b °
NHi 1632 ~~° ° ~ A 535.682 O\ 'NH
~NH
H°J ' °
NHi i °
1633 ° B 625.807 O_\ 'NH
'NH

V

NHi NI
%! Y 'O
1634 O~IINH B 743.942 NH
O
NHa 1635 O NH O A 623.791 NH
oti ////''~~~1 O
~~N
\N/
O O
O
1636 O\ 'NH B 673.935 ~.......... ~IINyH
/~ O
C J, N NHz ~ ~ ~~I/N
O O
1641 O NH O A 757.968 NH
O

~/
r~--~~ a b NHi ~ ~N
O O
1642 O NH O A 637.818 NH
OH
O
NHz O
1643 O NH O B 771.995 NH ~ _ a ////--~~~1 O
\ h 'N NHi ' / IIuIIO
1644 NH O A 651.845 NH
OH
a //~~ O
'N NHs \ / IIuIIO
O
1647 O\ /NH g 717.904 ~NH
al o a V
~ °
L ii .N NHi ~ ~ I~IO
1648 O-\ 'NH O B 597.753 \~NYH
\~
O
O O
1649 ° A 645.881 o\ 'NH
~NH
O' Y
O
1650 ° ° ° B 631.854 O~NH
~O~NH
~~::' O
b NHa \ / II~IIN
1651 ° ° ° A 609.764 O~NH
'NH
/ /J/IV~\O

O
NHa N
1652 ° ° ° A 623.791 O~NH
'NH
/ /J//Y~\0 V
°
NHi N
1653 ° B 653.817 o"NH
o °0 NH
~~ O
~N NHi / IIvIIN
O O
1654 ° A 603.801 O-\ 'NH
~NH
O' O
NHi O O
1655 ° A 617.827 o-\ 'NH
~NH
O' °
NHi 1656 ° ° ° A 589.774 o~NH "
~~NH

NHi N
1657 ° ° ° A 603.801 o\ 'NH
'NH
/ /J~~\0 O
NHi 1658 ° B 611.78 O\ 'NH
o ~ff NH
~~ O
b NHZ
1659 ° A 603.801 o\ 'NH
~NH
O' 1' °
NHa ° °
1660 ° A 589.774 O~NH
\,INvH
°
O
b~
1661 ~'''~° ° ° B 671.799 O~NH F
F F
NH
O
N
1662 ~"'~° ° ° B 629.838 O~NH
\~NyH
O
° °
1663 ° B 651.845 °\ 'NH
~NH
O' Y

O
~b IO O
1664 ° B 663.856 O\ 'NH
NHNH
b O
O °
1665 ° B 705.816 'NH F
\,IV F F
NH
V
_ °
NHs N
O O
1666 ° A 611.78 O-\ 'NH
~NH
O' O
NHZ
N
O O
1667 ° A 665.751 ~NH
\1y F F
F
~ /NH
O' V

1668 B 653.86 ° o 0 N"NH
o V

~~~NHz 1669 ~ ~ ~ ~ II~II A 625.807 ° °
~o 0 NH
V
V
°
NHi N
1670 ° ° ° A 589.774 o~NH
\1IN~H
O' O
~b 1671 ° ° ° B 617.827 o\ 'NH
~ /NHNH
o' Y

O
NHi N
O O
1672 ° A 603.801 O~NH
\~NyH
o' y f~~:
O
NHz N
O O
1673 ° B 617.827 Q\ 'NH
NHNH
O
O
NHi N
O O
1674 ° B 603.801 ~NH
~NH
..~.~~""
Fi?:: O
~b b~
' ~O °
1675 ° C 687.953 q\ 'NH
~NH

O
b~
O °
1676 ° B 683.921 O\ 'NH
~NH
O
NHi N
O O
1677 ° A 645.873 O-\ 'NH
~NH
O
O
NHi O O
1678 ° B 659.899 O~NH
\~NYH
~~ O
b NHi \ / IIuIIN
O O
1679 ° B 647.889 o-\ 'NH
~NH

V
°
N
O O
1680 - ° A 695.932 O~NH II
NH
O
V
°
~b b~
° °
1681 ° C 699.963 O~NH
\~NvH
O' X
V
°
Nh4j O O
1682 " ° B 671.910 ~NH
\INyH
o' V
/~ °
b NHi I~o 0 1683 ° A 657.884 O~NH
\~NyH
O

~~ O
'a NHi II~IIN
O O
1684 ° B 659.899 ~NH
\~NVH

O
~a a~
~° O
1685 ° B 655.868 O~NH II
~ /NH
O
V
O
a a O O
1686 ° C 659.899 o\ 'NH
~ /NHNH
O
/~ O
NHS
NN
O O
1687 ° A 617.820 O'\ 'NH '<' \,INCH
O

p NHi N

O O
1688 A 631.846 p NH
\
y ~
~N
H

Ki* range A = <75 nM; B = 75-250 nM; C = >250 nM
The present invention relates to novel HCV protease inhibitors. This utility can be manifested in their ability to inhibit the HCV NS2/NS4a serine protease. A general procedure for such demonstration is illustrated by the following in vitr~ assay.
Assay for HCV Protease Inhibitory Activity:
Spectrophotometric Assay: Spectrophotometric assay for the HCV serine protease can be performed on the inventive compounds by following the procedure described by R. Zhang et al, Analytical Biochemistry, 270 (1999) 268-275, the disclosure of which is incorporated herein by reference. The assay based on the proteolysis of chromogenic ester substrates is suitable for the continuous monitoring of HCV NS3 protease activity. The substrates are derived from the P side of the NS5A-NSSB junction sequence (Ac-DTEDVVX(Nva), where X = A or P) whose C-terminal carboxyl groups are esterified with one of four different chromophoric alcohols (3- or 4-nitrophenol, 7-hydroxy-4-methyl-coumarin, or 4-phenylazophenol). Illustrated below are the synthesis, characterization and application of these novel spectrophotometric ester substrates to high throughput screening and detailed kinetic evaluation of HCV NS3 protease inhibitors.
Materials and Methods:
Materials: Chemical reagents for assay related buffers are obtained from Sigma Chemical Company (St. Louis, Missouri). Reagents for peptide synthesis were from Aldrich Chemicals, Novabiochem (San Diego, California), Applied Biosystems (Foster City, California) and Perseptive Biosystems (Framingham, Massachusetts). Peptides are synthesized manually or on an automated ABI model 431A synthesizer (from Applied Biosystems). UV/VIS
Spectrometer model LAMBDA 12 was from Perkin Elmer (Norwalk, Connecticut) and 96-well UV plates were obtained from Corning (Corning, New York). The prewarming block can be from USA Scientific (Ocala, Florida) and the 96-well plate vortexer is from Labline Instruments (Melrose Park, Illinois). A Spectramax Plus microtiter plate reader with monochrometer is obtained from Molecular Devices (Sunnyvale, California).
Enzyme Preparation: Recombinant heterodimeric HCV NS3/NS4A protease (strain 1a) is prepared by using the procedures published previously (D. L.
Sali et al, Biochemistry, 37 (1998) 3392-3401 ). Protein concentrations are determined by the Biorad dye method using recombinant HCV protease standards previously quantified by amino acid analysis. Prior to assay initiation, the enzyme storage buffer (50 mM sodium phosphate pH 8.0, 300 mM NaCI, 10% glycerol, 0.05% lauryl maltoside and 10 mM DTT) is exchanged for the assay buffer (25 mM MOPS pH 6.5, 300 mM NaCI, 10%
glycerol, 0.05% lauryl maltoside, 5 pM EDTA and 5 pM DTT) utilizing a Biorad Bio-Spin P-6 prepacked column.
Substrate Synthesis and Purification: The synthesis of the substrates is done as reported by R. Zhang et al, (ibid.) and is initiated by anchoring Fmoc-Nva-OH to 2-chlorotrityl chloride resin using a standard protocol (K. Barlos et al, Int. J. Pept. Protein Res., 37 (1991 ), 513-520). The peptides are subsequently assembled, using Fmoc chemistry, either manually or on an automatic ABI
model 431 peptide synthesizer. The N-acetylated and fully protected peptide fragments are cleaved from the resin either by 10% acetic acid (HOAc) and 10% trifluoroethanol (TFE) in dichloromethane (DCM) for 30 min, or by 2%
trifluoroacetic acid (TFA) in DCM for 10 min. The combined filtrate and DCM
wash is evaporated azeotropically (or repeatedly extracted by aqueous Na2C03 solution) to remove the acid used in cleavage. The DCM phase is dried over Na2S04 and evaporated.
The ester substrates are assembled using standard acid-alcohol coupling procedures (K. Holmber et al, Acta Chem. Scand., B33 (1979) 410-412). Peptide fragments are dissolved in anhydrous pyridine (30-60 mg/ml) to which 10 molar equivalents of chromophore and a catalytic amount (0.1 eq.) of para-toluenesulfonic acid (pTSA) were added. Dicyclohexylcarbodiimide (DCC, 3 eq.) is added to initiate the coupling reactions. Product formation is monitored by HPLC and can be found to be complete following 12-72 hour reaction at room temperature. Pyridine solvent is evaporated under vacuum and further removed by azeotropic evaporation with toluene. The peptide ester is deprotected with 95% TFA in DCM for two hours and extracted three times with anhydrous ethyl ether to remove excess chromophore. The deprotected substrate is purified by reversed phase HPLC on a C3 or C8 column with a 30% to 60% acetonitrile gradient (using six column volumes).
The overall yield following HPLC purification can be approximately 20-30%.
The molecular mass can be confirmed by electrospray ionization mass spectroscopy. The substrates are stored in dry powder form under desiccation.
Spectra of Substrates and Products: Spectra of substrates and the corresponding chromophore products are obtained in the pH 6.5 assay buffer.
Extinction coefficients are determined at the optimal off-peak wavelength in 1-cm cuvettes (340 nm for 3-Np and HMC, 370 nm for PAP and 400 nm for 4-Np) using multiple dilutions. The optimal off-peak wavelength is defined as that wavelength yielding the maximum fractional difference in absorbance between substrate and product (product OD - substrate OD)/substrate OD).
Protease Assay: HCV protease assays are performed at 30°C using a 200 p1 reaction mix in a 96-well microtiter plate. Assay buffer conditions (25 mM
MOPS pH 6.5, 300 mM NaCI, 10% glycerol, 0.05% lauryl maltoside, 5 pM
EDTA and 5 pM DTT) are optimized for the NS3/NS4A heterodimer (D. L. Sali et al, ibid.)). Typically, 150 p1 mixtures of buffer, substrate and inhibitor are placed in wells (final concentration of DMSO <_4. % v/v) and allowed to preincubate at 30 °C for approximately 3 minutes. Fifty pls of prewarmed protease (12 nM, 30°C) in assay buffer, is then used to initiate the reaction (final volume 200 pl).The plates are monitored over the length of the assay (60 minutes) for change in absorbance at the appropriate wavelength (340 nm for 3-Np and HMC, 370 nm for PAP, and 400 nm for 4-Np) using a Spectromax Plus microtiter plate reader equipped with a monochrometer (acceptable results can be obtained with plate readers that utilize cutoff filters). Proteolytic cleavage of the ester linkage between the Nva and the chromophore is monitored at the appropriate wavelength against a no enzyme blank as a control for non-enzymatic hydrolysis. The evaluation of substrate kinetic parameters is performed over a 30-fold substrate concentration range (~6-200 pM). Initial velocities are determined using linear regression and kinetic constants are obtained by fitting the data to the Michaelis-Menten equation using non-linear regression analysis (Mac Curve Fit 1.1, K. Raner).
Turnover numbers (dccat) are calculated assuming the enzyme is fully active.
Evaluation of Inhibitors and Inactivators: The inhibition constants (Ki) for the competitive inhibitors Ac-D-(D-Gla)-L-I-(Cha)-C-OH (27), Ac-DTEDVVA(Nva)-OH and Ac-DTEDVVP(Nva)-OH are determined experimentally at fixed concentrations of enzyme and substrate by plotting vo/vi vs. inhibitor concentration ([I] o) according to the rearranged Michaelis-Menten equation for competitive inhibition kinetics: vo/vi = 1 + [I] o /(Ki (1 + [S] o /Km)), where vo is the uninhibited initial velocity, vi is the initial velocity in the presence of inhibitor at any given inhibitor concentration ([I]o) and [S]o is the substrate concentration used. The resulting data are fitted using linear regression and the resulting slope, 1/(Ki(1+[S] o/Km), is used to calculate the Ki value. The Ki* values of some of the inventive compounds are shown in Table 6 and Table 6A below:
Table 6 Exa# ple Structure (~~*~
nM
V
°
NHi N
° °
1654 °
~NH
\IINVH

V
°
NHz O O
1655 ° 24 O~NH
\INyH
~~ O
'N NHz \ / IIuIIN
O O
1631 ° 15 O-\ 'NH
~NH
O' Y
V
O
NHz N
1606 '~° ° ° 16 O\ 'NH
NHNH
i //~~ O
b NH2 NN
O O
1025 ° 6.7 o.\ 'NH
NH

V
~~ O
'N NHz \ / IIuIIN
O O
1024 ° 7.3 O~NH
\~NyH
V
O
O O
1086 ° 8 O\ 'NH
~NH
a V
,~k O
O O
1090 ° 9 O~NH II
NH
°
v V
:'yk °
~G b~
'' ~O °
1085 ° 11 o\ 'NH
° NHNH

_ °
° °
1023 ° 33 °\ 'NH
~°
~~II NH
/ 'N"O
H
V
_ °
N
O O

~NH
~NH
°
b ° °
1056 ° 30 °\ 'NH
~NH
°
NH
° O
1029 O\ /NH 14 J.....,.... NHNH
~b~°

°
~a ° °
1095 °
°\ 'NH
~NH
V
°
~b b~
N
O O
1098 ° 15 °\ 'NH
/ \ °°
NH
Table 6A
Exa# ple Structure ~K~*~
nM
°
NH
N
O °
O
1104 °~NH II 13 NH
b °

~~ NH
N
1103 °
~° ~' HN"O

NH
N
0 o °
HN
O
NH
N
o O
O
1112 O' 'NH II 20 °
~II NH
HN"O
//~~ O
NH
\ / IIuIIN
O O
1114 ° 32 q\ 'NH
~O
/I'I~ NH
HN' b NH
N
O O
1115 ° 7.4 ° NH
°II I I
HN"
//~~ O
NH
' ' IIuIIN
O O
1116 ° 34 O~NH
O \lIv ~II NH
HN"
O
NH
N
O O
1117 ° 19 o'\ 'NH
~0I
~I[ NH
HN"O
NH
~ ~I,I/N
O O
1120 ° 30 O~NH
\~vO
~ NH
HN"

While the present invention has been described with in conjunction with the specific embodiments set forth above, many alternatives, modifications and other variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the present invention.

Claims (37)

1. A compound, or enantiomers, stereoisomers, rotamers, tautomers, or racemates of said compound, or a pharmaceutically acceptable salt, solvate or ester of said compound, said compound having the general structure shown in Formula I:
wherein:
R1 is H, OR8, NR9R10, or CHR9R10, wherein R8, R9 and R10 can be the same or different, each being independently selected from the group consisting of H, alkyl-, alkenyl-, alkynyl-, aryl-, heteroalkyl-, heteroaryl-, cycloalkyl-, heterocyclyl-, arylalkyl-, and heteroarylalkyl;
A and M can be the same or different, each being independently selected from R, OR, NHR, NRR', SR, SO2R, and halo; or A and M are connected to each other such that the moiety:
shown above in Formula I forms either a three, four, six, seven or eight-membered cycloalkyl, a four to eight-membered heterocyclyl, a six to ten-membered aryl, or a five to ten-membered heteroaryl;
E is C(H) or C(R);
L is C(H), C(R), CH2C(R), or C(R)CH2;
R, R', R2, and R3 can be the same or different, each being independently selected from the group consisting of H, alkyl-, alkenyl-, alkynyl-, cycloalkyl-, heteroalkyl-, heterocyclyl-, aryl-, heteroaryl-, (cycloalkyl)alkyl-, (heterocyclyl)alkyl-, aryl-alkyl-, and heteroaryl-alkyl-;
or alternately R and R' in NRR' are connected to each other such that NRR' forms a four to eight-membered heterocyclyl;
and Y is selected from the following moieties:
wherein G is NH or O; and R15, R16, R17, R18, and R19 can be the same or different, each being independently selected from the group consisting of H, alkyl, heteroalkyl, alkenyl, heteroalkenyl, alkynyl, heteroalkynyl, cycloalkyl, heterocyclyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, or alternately, (i) either R15 and R16 are connected to each other to form a four to eight-membered cyclic structure, or R15 and R19 are connected to-each other to form a four to eight-membered cyclic structure, and (ii) likewise, independently, R17 and R18 are connected to each other to form a three to eight-membered cycloalkyl or heterocyclyl;
wherein each of said alkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl can be unsubstituted or optionally independently substituted with one or more moieties selected from the group consisting of: hydroxy, alkoxy, aryloxy, thio, alkylthio, arylthio, amino, amido, alkylamino, arylamino, alkylsulfonyl, arylsulfonyl, sulfonamido, alkylsulfonamido, arylsulfonamido, alkyl, aryl, heteroaryl, keto, carboxy, carbalkoxy, carboxamido, alkoxycarbonylamino, alkoxycarbonyloxy, alkylureido, arylureido, halo, cyano, and nitro.

2. The compound of claim 1, wherein R1 is NR9R10, and R9 is H, R10 is H, or R14 wherein R14 is H, alkyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, alkyl-aryl, alkyl-heteroaryl, aryl-alkyl, alkenyl, alkynyl or heteroaryl-alkyl.

3. The compound of claim 2, wherein R14 is selected from the group consisting of:

4. The compound of claim 1, wherein R2 is selected from the group consisting of the following moieties:

5. The compound of claim 1, wherein R3 is selected from the group consisting of:

wherein R31 is OH or O-alkyl; and R32 is H, C(O)CH3, C(O)OtBu or C(O)N(H)tBu.

6. The compound of claim 5, wherein R3 is selected from the group consisting of the following moieties:

7. The compound of claim 1, wherein Y is selected from the following moieties:
wherein G = NH or O; and R15, R16, R17, R18, and R19 can be the same or different, each being independently selected from the group consisting of H, alkyl, heteroalkyl, alkenyl, heteroalkenyl, alkynyl, heteroalkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, or alternately, (i) either R15 and R16 are directly connected to form a four to eight-membered cyclic structure, or R15 and R19 are directly connected to form a four to eight-membered cyclic structure, and (ii) likewise, independently, R17 and R18 are directly connected to form a three to eight-membered cycloalkyl or heterocyclyl;
wherein each of said alkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl can be unsubstituted or optionally independently substituted with one or more moieties selected from the group consisting of: hydroxy, alkoxy, aryloxy, thio, alkylthio, arylthio, amino, amido, alkylamino, arylamino, alkylsulfonyl, arylsulfonyl, sulfonamido, alkylsulfonamido, arylsulfonamido, keto, carboxy, carbalkoxy, carboxamido, alkoxycarbonylamino, alkoxycarbonyloxy, alkyfureido, arylureido, halo, cyano, and nitro.

8. The compound of claim 7, wherein G is NH.

9. The compound of claim 8, wherein is selected from the group consisting of:
wherein Y32 is selected from the group consisting of:
R16 is selected from H, methyl, phenyl, benzyl; and R15 and R19 maybe the same or different, each being independently selected from the following:
or alternately, the moiety:
is selected from the following moieties:

10. The compound of claim 9, wherein R16 is H.

11. The compound of claim 1, wherein the moiety:
is selected from the following structures:

12. The compound of claim 11, wherein the moiety:

is selected from the following structures:

13. The compound of claim 12, wherein the moiety:
is selected from the following structures:

14. The compound of claim 1, wherein R14 is selected from the group consisting of:
R2 is selected from the group consisting of the following moieties:
R3 is selected from the group consisting of the following moieties:
Y is selected from the group consisting of:

wherein G = NH; and the moiety:
is selected from the group consisting of:
R16 = H; and R15 and R19 maybe the same or different, and is selected from one of the following:

or alternately, the moiety:
is represented by one of the following moieties, and the moiety:

15. A pharmaceutical composition comprising as an active ingredient at least one compound of claim 1.

16. The pharmaceutical composition of claim 15 for use in treating disorders associated with HCV.

17. The pharmaceutical composition of claim 16 additionally comprising at least one pharmaceutically acceptable carrier.

18. The pharmaceutical composition of claim 17, additionally containing at least one antiviral agent.

19. The pharmaceutical composition of claim 18, still additionally containing at least one interferon.

20. The pharmaceutical composition of claim 19, wherein said at least one antiviral agent is ribavirin and said at least one interferon is .alpha.-interferon or pegylated interferon.

21. A method of treating disorders associated with the HCV, said method comprising administering to a patient in need of such treatment a pharmaceutical composition which comprises therapeutically effective amounts of at least one compound of claim 1.

22. The method of claim 21, wherein said administration is oral or subcutaneous.

23. The use of a compound of claim 1 for the manufacture of a medicament to treat disorders associated with the HCV.

24. A method of preparing a pharmaceutical composition for treating the disorders associated with the HCV, said method comprising bringing into intimate physical contact at least one compound of claim 1 and at least one pharmaceutically acceptable carrier.

25. A compound exhibiting HCV protease inhibitory activity, or enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates of said compound, or a pharmaceutically acceptable salt, solvate or ester of said compound, said compound being selected from the compounds of structures listed below:

26. A pharmaceutical composition for treating disorders associated with the HCV, said composition comprising therapeutically effective amount of one or more compounds in claim 25 and a pharmaceutically acceptable carrier.

27. The pharmaceutical composition of claim 26, additionally containing at least one antiviral agent.

28. The pharmaceutical composition of claim 27, additionally containing at least one interferon or PEG-interferon alpha conjugate.

29. The pharmaceutical composition of claim 28, wherein said at least one antiviral agent is ribavirin and said at least one interferon is .alpha.-interferon or pegylated interferon.

30. A method of treatment of a hepatitis C virus associated disorder, comprising administering an effective amount of one or more compounds of claim 25.

31. A method of modulating the activity of hepatitis C virus (HCV) protease, comprising contacting HCV protease with one or more compounds of claim 25.

32. A method of treating, preventing, or ameliorating one or more symptoms of hepatitis C, comprising administering a therapeutically effective amount of one or more compounds of claim 25.

33. The method of claim 32, wherein the HCV protease is the NS3/NS4a protease.

34. The method of claim 33, wherein the compound or compounds inhibit HCV NS3/NS4a protease.

35. A method of modulating the processing of hepatitis C virus (HGV) polypeptide, comprising contacting a composition containing the HCV
polypeptide under conditions in which said polypeptide is processed with one or more compounds of claim 25.

36. A method of treating disorders associated with the HCV, said method comprising administering to a patient in need of such treatment, a pharmaceutical composition which comprises therapeutically effective amounts of at least one compound, or enantiomers, stereoisomers, rotamers, tautomers, diastereomers or racemates of said compound, or a pharmaceutically acceptable salt, solvate or ester of said compound, said compound being selected from the following:

37. A compound of claim 1 in purified form.